<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE patent-document
  PUBLIC "-//MXW//DTD patent-document XML//EN" "http://www.matrixware.com/dtds/patents/v1.2/patent-document.dtd"><patent-document ucid="EP-1903114-A2" country="EP" doc-number="1903114" kind="A2" lang="EN" family-id="39103446" status="new" date-produced="20090523" date="20080326"><bibliographic-data><publication-reference ucid="EP-1903114-A2" status="new" fvid="88437182"><document-id status="new" format="original"><country>EP</country><doc-number>1903114</doc-number><kind>A2</kind><date>20080326</date></document-id></publication-reference><application-reference ucid="EP-07022730-A" status="new" is-representative="NO"><document-id status="new" format="epo"><country>EP</country><doc-number>07022730</doc-number><kind>A</kind><date>19981201</date></document-id></application-reference><priority-claims status="new"><priority-claim ucid="EP-98962858-A" status="new"><document-id status="new" format="epo"><country>EP</country><doc-number>98962858</doc-number><kind>A</kind><date>19981201</date></document-id></priority-claim><priority-claim ucid="US-20320098-A" status="new"><document-id status="new" format="epo"><country>US</country><doc-number>20320098</doc-number><kind>A</kind><date>19981130</date></document-id></priority-claim><priority-claim ucid="US-6769397-P" status="new"><document-id status="new" format="epo"><country>US</country><doc-number>6769397</doc-number><kind>P</kind><date>19971201</date></document-id></priority-claim></priority-claims><technical-data status="new"><classifications-ipcr><classification-ipcr status="new">C12P   7/64        20060101ALI20080214BHEP        </classification-ipcr><classification-ipcr status="new">C12P   7/64        20060101CLI20080214BHEP        </classification-ipcr><classification-ipcr status="new">C12P  19/00        20060101CFI20080214BHEP        </classification-ipcr><classification-ipcr status="new">C12P  19/04        20060101ALI20080214BHEP        </classification-ipcr><classification-ipcr status="new">C12P  19/12        20060101ALI20080214BHEP        </classification-ipcr><classification-ipcr status="new">C12P  19/18        20060101ALI20080214BHEP        </classification-ipcr><classification-ipcr status="new">C12P  19/26        20060101ALI20080214BHEP        </classification-ipcr><classification-ipcr status="new">C12P  19/44        20060101AFI20080214BHEP        </classification-ipcr></classifications-ipcr><classification-ecla status="new"><classification-symbol scheme="EC">C12P  19/18</classification-symbol><classification-symbol scheme="EC">C12P  19/26</classification-symbol></classification-ecla><invention-title load-source="ep" status="new" lang="DE">Enzymatische Synthese von Gangliosiden</invention-title><invention-title load-source="ep" status="new" lang="EN">Enzymatic synthesis of gangliosides</invention-title><invention-title load-source="ep" status="new" lang="FR">Synthèse enzymatique de gangliosides</invention-title><citations><patent-citations><patcit ucid="EP-0344955-A2" status="new"><document-id status="new" format="epo"><country>EP</country><doc-number>0344955</doc-number><kind>A2</kind></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit ucid="EP-0475354-A2" status="new"><document-id status="new" format="epo"><country>EP</country><doc-number>0475354</doc-number><kind>A2</kind></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit ucid="US-4235871-A" status="new"><document-id status="new" format="epo"><country>US</country><doc-number>4235871</doc-number><kind>A</kind></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit ucid="US-4347244-A" status="new"><document-id status="new" format="epo"><country>US</country><doc-number>4347244</doc-number><kind>A</kind></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit ucid="US-4501728-A" status="new"><document-id status="new" format="epo"><country>US</country><doc-number>4501728</doc-number><kind>A</kind></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit ucid="US-4603044-A" status="new"><document-id status="new" format="epo"><country>US</country><doc-number>4603044</doc-number><kind>A</kind></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit ucid="US-4710490-A" status="new"><document-id status="new" format="epo"><country>US</country><doc-number>4710490</doc-number><kind>A</kind></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit ucid="US-4837028-A" status="new"><document-id status="new" format="epo"><country>US</country><doc-number>4837028</doc-number><kind>A</kind></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit ucid="US-4887931-A" status="new"><document-id status="new" format="epo"><country>US</country><doc-number>4887931</doc-number><kind>A</kind></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit ucid="US-4957773-A" status="new"><document-id status="new" format="epo"><country>US</country><doc-number>4957773</doc-number><kind>A</kind></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit ucid="US-5352670-A" status="new"><document-id status="new" format="epo"><country>US</country><doc-number>5352670</doc-number><kind>A</kind></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit ucid="US-5369017-A" status="new"><document-id status="new" format="epo"><country>US</country><doc-number>5369017</doc-number><kind>A</kind></document-id><sources><source category="X" name="SEA" created-by-npl="N"/></sources></patcit><patcit ucid="US-5374541-A" status="new"><document-id status="new" format="epo"><country>US</country><doc-number>5374541</doc-number><kind>A</kind></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit ucid="US-5403726-A" status="new"><document-id status="new" format="epo"><country>US</country><doc-number>5403726</doc-number><kind>A</kind></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit ucid="US-5409817-A" status="new"><document-id status="new" format="epo"><country>US</country><doc-number>5409817</doc-number><kind>A</kind></document-id><sources><source category="X" name="SEA" created-by-npl="N"/></sources></patcit><patcit ucid="US-5728554-A" status="new"><document-id status="new" format="epo"><country>US</country><doc-number>5728554</doc-number><kind>A</kind></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit ucid="US-6030815-A" status="new"><document-id status="new" format="epo"><country>US</country><doc-number>6030815</doc-number><kind>A</kind></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit ucid="US-6454946-B1" status="new"><document-id status="new" format="epo"><country>US</country><doc-number>6454946</doc-number><kind>B1</kind></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit ucid="WO-1992016640-A1" status="new"><document-id status="new" format="epo"><country>WO</country><doc-number>1992016640</doc-number><kind>A1</kind></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit ucid="WO-1994016731-A1" status="new"><document-id status="new" format="epo"><country>WO</country><doc-number>1994016731</doc-number><kind>A1</kind></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit ucid="WO-1996032491-A1" status="new"><document-id status="new" format="epo"><country>WO</country><doc-number>1996032491</doc-number><kind>A1</kind></document-id><sources><source category="X" name="SEA" created-by-npl="N"/></sources></patcit></patent-citations><non-patent-citations><nplcit status="new"><text>ALAIS; VEYRIERIES CARBOHYDRATE RES vol. 207, 1990, pages 11 - 31</text><sources><source name="APP" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>BAST ET AL. J. CELL BIOL. vol. 116, 1992, pages 423 - 435</text><sources><source name="APP" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>BEELEY: 'Laboratory Techniques in Biochemistry and Molecular Biology,', 1985, ELSEVIER</text><sources><source name="APP" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>BEITH-HALAHMI ET AL. CARBOHYDRATE RES. vol. 5, 1967, pages 25 - 30</text><sources><source name="APP" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>CHICKEN, KUROSAWA ET AL. J. BIOL. CHEM. vol. 269, 1994, pages 19048 - 19053</text><sources><source name="APP" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>COSTA ET AL.: 'Cirrhosis, Hyperammonemia, and Hepatic Encephalopathy', 1994, PLENUM PRESS page 129</text><sources><source name="APP" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>DACREMONT ET AL. BIOCHIM. BIOPHYS. ACTA vol. 424, pages 315 - 322</text><sources><source name="APP" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>DEVLIN: 'Textbook of Biochemistry', 1992, WILEY-LISS</text><sources><source name="APP" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>EL RASSI: 'Carbohydrate Analysis : High Performance Liquid Chromatography and Capillarv Electrophoresis', vol. 58, 1994, ELSEVIER SCIENCE LTD</text><sources><source name="APP" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>'Gangliosides and Cancer', 1989, VCH pages 10 - 15</text><sources><source name="APP" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>GAUDINO JOHN J ET AL:  "A novel and efficient synthesis of neolacto series gangliosides 3'-nLM-1 and 6'nLM-1" JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 116, no. 3, 1994, pages 1149-1150, XP002464788 ISSN: 0002-7863</text><sources><source category="X" name="SEA" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>GAUDINO; PAULSON AM. CHEM. SOC. vol. 116, 1994, pages 1149 - 1150</text><sources><source name="APP" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>GHOSH ET AL. GLYCOCONJ. J vol. 12, 1995, pages 838 - 47</text><sources><source name="APP" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>GILBERT ET AL. J. BIOL. CHEM. vol. 271, 1996, pages 28271 - 28276</text><sources><source name="APP" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>GROSS ET AL. EUR. 1. BIOCHEM vol. 168, 1987, page 595</text><sources><source name="APP" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>GRUDLER; SCHMIDT CARBOHYDRATE RES vol. 135, 1985, pages 203 - 218</text><sources><source name="APP" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>GRUNDMANN ET AL. NUCL. ACIDS RES vol. 18, 1990, page 667</text><sources><source name="APP" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>GUADINO; PAULSON J. AM. CHEM. SOC. vol. 116, 1994, pages 1149 - 1150</text><sources><source name="APP" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>HAMAMOTO ET AL. BIOORG. MED. CHEM vol. 1, 1993, pages 141 - 145</text><sources><source name="APP" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>HARAGUCHI ET AL. PROC. NATL. ACAD. SCI. USA vol. 91, 1994, pages 10455 - 10459</text><sources><source name="APP" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>HARLOW; LANE: 'Antibodies, A Laboratory Manual', 1988, COLD SPRING HARBOR PUBLICATIONS</text><sources><source name="APP" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>HASEGAWA ET AL. 1. CARBOHYDRATE CHEM vol. 10, 1991, pages 439 - 459</text><sources><source name="APP" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>HASEGAWA ET AL. CARBOHYDRATE CHEM vol. 10, 1991, pages 439 - 459</text><sources><source name="APP" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>HIDARI ET AL. BIOCHEM. J. vol. 301, 1994, pages 957 - 965</text><sources><source name="APP" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>HIGA ET AL. J. BIOL. CHEM vol. 260, 1985, page 8838</text><sources><source name="APP" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>HILDEBRAND ET AL. BIOCHIM. BIOPHYS. ACTA vol. 260, 1972, pages 272 - 278</text><sources><source name="APP" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>HOROWITZ ADV. EXP. MED. AND BIOL vol. 174, 1988, pages 593 - 600</text><sources><source name="APP" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>HOUNSELL: 'Glycoanalysis Protocols' METH. MOL. BIOL vol. 76, 1998,</text><sources><source name="APP" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>ICHIKAWA ET AL. PROC. NAT'L. ACAD. SCI. vol. 93, 1996, pages 4638 - 4643</text><sources><source name="APP" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>ICHIKAWA ET AL:  "Enzyme-Catalyzed synthesis  of sialyl Oligosaccharide with in Situ Regeneration of CMP-Sialic Acid" JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 113, 1991, - 1991 pages 4698-4700, XP002464789</text><sources><source category="X" name="SEA" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>ICHIKAWA; HIRABAYASHI TRENDS CELL BIOL vol. 8, 1998, pages 198 - 202</text><sources><source name="APP" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>ISHII GLYCOCONJ. J vol. 14, no. 1, 1997, page 49</text><sources><source name="APP" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>ITO Y ET AL:  "A noval strategy for synthesis of ganglioside GM3 using an enzymatically produced sialoside glycosyl donor" JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, DC, US, vol. 115, no. 4, 1993, pages 1603-1605, XP002966172 ISSN: 0002-7863</text><sources><source category="A" name="SEA" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>KAMEYAMA ET AL. CARBOHYDRATE RES vol. 193, 1989, pages CL - C5</text><sources><source name="APP" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>KANAMORI ET AL. J. BIOL. CHEM. vol. 265, 1990, pages 21811 - 21819</text><sources><source name="APP" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>KANNAGI ET AL. J. BIOL. CHEM. vol. 257, 1982, page 14865</text><sources><source name="APP" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>KAPITONOV; YU BIOCHEM. BIOPHYS. RES. COMMUN vol. 232, 1997, pages 449 - 453</text><sources><source name="APP" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>KARPIATZ ET AL. ADV. EXP. MED. AND BIOL vol. 174, 1984, pages 489 - 497</text><sources><source name="APP" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>KHARLAMOV ET AL. PROC. NAT '!. ACAD. SCI. USA vol. 91, 1994, pages 6303 - 6307</text><sources><source name="APP" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>KHARLAMOV ET AL. PROC. NAT'L. ACAD. SCI. vol. 91, 1994, pages 6303 - 6307</text><sources><source name="APP" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>KITAGAWA ET AL. J. BIOL. CHEM. vol. 271, 1996, pages 931 - 938</text><sources><source name="APP" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>KITAGAWA; PAULSON J. BIOL. CHEM. vol. 269, 1994, pages 1394 - 1401</text><sources><source name="APP" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>KLOCK ET AL. BLOOD CELLS vol. 7, 1981, page 247</text><sources><source name="APP" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>KUROSAWA ET AL. EUR. 1. BIOCHEM. vol. 219, 1994, pages 375 - 381</text><sources><source name="APP" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>KUROSAWA ET AL. J. BIOL. CHEM vol. 269, 1994, pages 1402 - 1409</text><sources><source name="APP" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>LANGER SCIENCE vol. 249, 1990, pages 1527 - 1533</text><sources><source name="APP" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>LEDEEN ET AL. J. NEUROCHEM vol. 21, 1973, page 829</text><sources><source name="APP" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>LEDEEN; YU METHODS ENZYMOL. vol. 83, 1982, page 139</text><sources><source name="APP" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>LEHNINGER: 'Biochemistry', 1981, WORTH PUBLISHERS pages 287 - 295</text><sources><source name="APP" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>LIVINGSTON ET AL. VACCINE vol. 11, 1993, page 1199</text><sources><source name="APP" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>MACHER ET AL. BIOL. CHEM vol. 256, 1981, pages 1968 - 1974</text><sources><source name="APP" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>MAGNANI ET AL. ANAL. BIOCHEM. vol. 109, 1980, page 399</text><sources><source name="APP" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>MAHADNIK ET AL. DRUG DEVELOPMENT RES vol. 15, 1988, pages 337 - 360</text><sources><source name="APP" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>MURASE ET AL. CARBOHYDRATE RES vol. 188, 1989, pages 71 - 80</text><sources><source name="APP" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>NADANO ET AL. J. BIOL. CHEM. vol. 261, 1986, pages 11550 - 11557</text><sources><source name="APP" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>NAGATA ET AL. J. BIOL. CHEM. vol. 267, 1992, pages 12082 - 12087</text><sources><source name="APP" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>NAKAYAMA ET AL. J. BIOL. CHEM. vol. 271, 1996, pages 3684 - 3691</text><sources><source name="APP" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>NARA ET AL. PROC. NATL. ACAD. SCI. USA vol. 91, 1994, pages 7952 - 7956</text><sources><source name="APP" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>NILSSON ET AL. TRENDS BIOTECHNOL. vol. 6, 1988, page 256</text><sources><source name="APP" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>NOBILE-ORAZIO ET AL. DRUGS vol. 47, 1994, pages 576 - 585</text><sources><source name="APP" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>NOJIRI ET AL. BIOL. CHEM vol. 263, 1988, pages 7443 - 7446</text><sources><source name="APP" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>NOMURA ET AL. BIOL. CHEM vol. 273, 1998, pages 13570 - 7</text><sources><source name="APP" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>PAULSON ET AL. CARBOHYDRATE RES vol. 137, 1985, pages 39 - 62</text><sources><source name="APP" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>PAULSON ET AL. J. BIOL. CHEM vol. 253, 1978, pages 5617 - 5624</text><sources><source name="APP" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>PONPIPOM ET AL. TETRAHEDRON LETT. 1978, pages 1717 - 1720</text><sources><source name="APP" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>'Remington's Pharmaceutical Sciences', 1985, MACE PUBLISHING COMPANY</text><sources><source name="APP" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>RODDEN ET AL. NEUROSURG vol. 74, 1991, pages 606 - 619</text><sources><source name="APP" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>SAMSON DRUG DEVEL. REV vol. 19, 1990, pages 209 - 224</text><sources><source name="APP" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>SANGO ET AL. GENOMICS vol. 27, 1995, pages 362 - 365</text><sources><source name="APP" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>SASAKI ET AL. 1. BIOL. CHEM. vol. 268, 1993, pages 22782 - 22787</text><sources><source name="APP" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>SASAKI ET AL. J. BIOL. CHEM. vol. 268, 1993, pages 22782 - 22787</text><sources><source name="APP" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>SASAKI ET AL. J. BIOL. CHEM. vol. 269, 1994, pages 15950 - 15956</text><sources><source name="APP" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>SCHEIDEGGER ET AL. J. BIOL. CHEM. vol. 270, 1995, pages 22685 - 22688</text><sources><source name="APP" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>SCHNEIDER ANN. N.Y. ACAD. SCI vol. 845, 1998, pages 363 - 73</text><sources><source name="APP" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>SCHNEIDER ET AL. NEUROLOGY vol. 44, 1994, page 748</text><sources><source name="APP" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>SCHWARZMANN; SANDHOFF METH. ENZYMOL vol. 138, 1987, pages 319 - 341</text><sources><source name="APP" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>SHAMES ET AL. GLYCOBIOLOGY vol. 1, 1991, page 187</text><sources><source name="APP" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>SHAPER ET AL. 1. BIOL. CHEM vol. 263, 1988, pages 10420 - 10428</text><sources><source name="APP" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>'Sialic Acids: Chemistry, Metabolism and Function', 1992, SPRINGER-VERLAG</text><sources><source name="APP" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>SJOBERG ET AL. 1. BIOL. CHEM. vol. 271, 1996, pages 7450 - 7459</text><sources><source name="APP" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>SKAPER ET AL. MOL. NEUROBIOL. vol. 3, 1989, page 173</text><sources><source name="APP" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>SPELLMAN ET AL. J. BIOL. CHEM. vol. 264, 1989, page 14100</text><sources><source name="APP" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>ST. LOUIS, MO; BOEHRINGER MANNHEIM SIGMA CHEM. CO</text><sources><source name="APP" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>STAMENKOVIC ET AL. J. EXP. MED vol. 172, 1990, pages 641 - 643</text><sources><source name="APP" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>STANLEY ET AL. J. BIOL. CHEM vol. 263, 1988, page 11374</text><sources><source name="APP" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>SZOKA ET AL. ANN. REV. BIOPHYS. BIOENG vol. 9, 1980, page 467</text><sources><source name="APP" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>TSUJI ET AL. GLYCOBIOLOGY vol. 6, 1996, pages V - XIV</text><sources><source name="APP" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>US 7107698            P 15 January 1998</text><sources><source name="APP" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>VAN DEN EIJNDEN ET AL. J. BIOL. CHEM. vol. 256, 1991, page 3159</text><sources><source name="APP" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>VANN ET AL. J. BIOL. CHEM vol. 262, 1987, page 17556</text><sources><source name="APP" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>VARKI GLYCOBIOLOGY vol. 2, 1992, pages 25 - 40</text><sources><source name="APP" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>VIJAY ET AL. J. BIOL. CHEM. vol. 250, 1975, page 164</text><sources><source name="APP" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>WEINSTEIN ET AL. J. BIOL. CHEM. vol. 257, 1982, page 13845</text><sources><source name="APP" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>WEINSTEIN ET AL. J. BIOL. CHEM. vol. 262, 1987, pages 17735 - 17743</text><sources><source name="APP" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>WEN ET AL. J. BIOL. CHEM. vol. 267, 1992, pages 21011 - 21019</text><sources><source name="APP" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>WIEGANDT H-S. ZSCHR. PHYSIOL. CHEM vol. 354, 1973, pages 1049 - 1056</text><sources><source name="APP" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>YAMAMOTO ET AL. J. BIOCHEM. vol. 120, 1996, pages 104 - 110</text><sources><source name="APP" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>YOSHIDA ET AL. J. BIOL. CHEM. vol. 270, 1995, pages 14628 - 14633</text><sources><source name="APP" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>ZAPATA ET AL. J. BIOL. CHEM vol. 264, 1989, page 14769</text><sources><source name="APP" created-by-npl="N"/></sources></nplcit></non-patent-citations></citations></technical-data><related-documents status="new"><relation type="division"><child-doc ucid="EP-07022730-A"><document-id status="new" format="original"><country>EP</country><doc-number>07022730</doc-number><kind>A</kind><date>19981201</date></document-id></child-doc><parent-doc ucid="EP-98962858-A" psta="unknown"><document-id status="new" format="original"><country>EP</country><doc-number>98962858</doc-number><kind>A</kind><date>19981201</date></document-id></parent-doc></relation></related-documents><parties><applicants><applicant status="new" format="epo"><addressbook><name>NEOSE TECHNOLOGIES INC</name><address><country>US</country></address></addressbook></applicant><applicant status="new" format="intermediate"><addressbook><name>NEOSE TECHNOLOGIES, INC.</name></addressbook></applicant><applicant status="new" format="original"><addressbook><last-name>Neose Technologies, Inc.</last-name><address><street>102 Witmer Road</street><city>Horsham, PA 19044</city><country>US</country></address></addressbook></applicant></applicants><inventors><inventor status="new" format="epo"><addressbook><name>DEFREES SHAWN</name><address><country>US</country></address></addressbook></inventor><inventor status="new" format="intermediate"><addressbook><name>DEFREES, SHAWN</name></addressbook></inventor><inventor status="new" format="original"><addressbook><last-name>DEFREES, SHAWN</last-name><address><street>126 Filly Drive</street><city>North Wales PA 19454</city><country>US</country></address></addressbook></inventor></inventors><agents><agent status="new" format="original"><addressbook><last-name>Cripps, Joanna Elizabeth</last-name><address><street>Mewburn Ellis LLP York House 23 Kingsway</street><city>London WC2B 6HP</city><country>GB</country></address></addressbook></agent></agents></parties><international-convention-data><designated-states><ep-contracting-states><country>AT</country><country>BE</country><country>CH</country><country>CY</country><country>DE</country><country>DK</country><country>ES</country><country>FI</country><country>FR</country><country>GB</country><country>GR</country><country>IE</country><country>IT</country><country>LI</country><country>LU</country><country>MC</country><country>NL</country><country>PT</country><country>SE</country></ep-contracting-states></designated-states></international-convention-data></bibliographic-data><abstract load-source="ep" status="new" lang="EN"><p num="pa01">This invention provides methods for practical <i>in vitro</i> synthesis of gangliosides and other glycolipids. The synthetic methods typically involve enzymatic synthesis, or a combination of enzymatic and chemical synthesis. One or more of the enzymatic steps is preferably carried out in the presence of an organic solvent.</p></abstract><description load-source="ep" status="new" lang="EN"><heading><b><u style="single">BACKGROUND OF THE INVENTION</u></b></heading><heading><b><u style="single">Field of the Invention</u></b></heading><p num="p0001">This invention pertains to the field of <i>in vitro</i> enzymatic synthesis of gangliosides and related compounds.</p><heading><b><u style="single">Background</u></b></heading><p num="p0002">Gangliosides are a class of glycolipids, often found in cell membranes, that consist of three elements. One or more sialic acid residues are attached to an oligosaccharide or carbohydrate core moiety, which in turn is attached to a hydrophobic lipid (ceramide) structure which generally is embedded in the cell membrane. The ceramide moiety includes a long chain base (LCB) portion and a fatty acid (FA) portion. Gangliosides, as well as other glycolipids and their structures in general, are discussed in, for example, <nplcit id="ncit0001" status="new" npl-type="b"><text>Lehninger, Biochemistry (Worth Publishers, 1981) pp. 287-295</text></nplcit> and <nplcit id="ncit0002" status="new" npl-type="b"><text>Devlin, Textbook of Biochemistry (Wiley-Liss, 1992</text></nplcit>). Gangliosides are classified according to the number of monosaccharides in the carbohydrate moiety, as well as the number and location of sialic acid groups present in the carbohydrate moiety. Monosialogangliosides are given the designation "GM", disialogangliosides are designated "GD", trisialogangliosides "GT", and tetrasialogangliosides are designated "GQ". Gangliosides can be classified further depending on the position or positions of the sialic acid residue or residues bound. Further classification is based on the number of saccharides present in the oligosaccharide core, with the subscript "1" designating a ganglioside that has four saccharide residues (Gal-GalNAc-Gal-Glc-Ceramide), and the subscripts "2", "3" and "4" representing trisaccharide (GalNAc-Gal-Glc-Ceramide), disaccharide (Gal-Glc-Ceramide) and monosaccharide (Gal-Ceramide) gangliosides, respectively.</p><p num="p0003">Gangliosides are most abundant in the brain, particularly in nerve endings. They are believed to be present at receptor sites for neurotransmitters, including acetylcholine, and can also act as specific receptors for other biological macromolecules, including interferon, hormones, viruses, bacterial toxins, and the like. Gangliosides are have<!-- EPO <DP n="2"> --> been used for treatment of nervous system disorders, including cerebral ischemic strokes. <i>See, e.g.,</i><nplcit id="ncit0003" status="new" npl-type="s"><text>Mahadnik et al. (1988) Drug Development Res. 15: 337-360</text></nplcit>; <patcit id="pcit0001" dnum="US4710490A" status="new"><text>US Patent Nos. 4,710,490</text></patcit> and <patcit id="pcit0002" dnum="US4347244A" status="new"><text>4,347,244</text></patcit>; <nplcit id="ncit0004" status="new" npl-type="s"><text>Horowitz (1988) Adv. Exp. Med. and Biol. 174: 593-600</text></nplcit>; <nplcit id="ncit0005" status="new" npl-type="s"><text>Karpiatz et al. (1984) Adv. Exp. Med. and Biol. 174: 489-497</text></nplcit>.</p><p num="p0004">Certain gangliosides are found on the surface of human hematopoietic cells (<nplcit id="ncit0006" status="new" npl-type="s"><text>Hildebrand et al. (1972) Biochim. Biophys. Acta 260: 272-278</text></nplcit>; <nplcit id="ncit0007" status="new" npl-type="s"><text>Macher et al. (1981) J. Biol. Chem. 256: 1968-1974</text></nplcit>; <nplcit id="ncit0008" status="new" npl-type="s"><text>Dacremont et al. Biochim. Biophys. Acta 424: 315-322</text></nplcit>; <nplcit id="ncit0009" status="new" npl-type="s"><text>Klock et al. (1981) Blood Cells 7: 247</text></nplcit>) which may play a role in the terminal granulocytic differentiation of these cells. <nplcit id="ncit0010" status="new" npl-type="s"><text>Nojiri et al. (1988) J. Biol. Chem. 263: 7443-7446</text></nplcit>. These gangliosides, referred to as the "neolacto" series, have neutral core oligosaccharide structures having the formula [Galβ-(1,4)GlcNAcβ(1,3)]<sub>n</sub>Galβ(1,4)Glc, where n = 1-4. Included among these neolacto series gangliosides are 3'-nLM<sub>1</sub> (NeuAcα(2,3)Galβ(1,4)GlcNAcβ(1,3)Galβ(1,4)-Glcβ(1,1)-Ceramide) and 6'-nLM<sub>1</sub> (NeuAcα(2,6)Galβ(1,4)GlcNAcβ(1,3)Galβ(1,4)-Glcβ(1,1)-Ceramide).</p><p num="p0005">The use of gangliosides as therapeutic reagents, as well as the study of ganglioside function, would be facilitated by convenient and efficient methods of synthesizing desired gangliosides. A combined enzymatic and chemical approach to synthesis of 3'-nLM, and 6'-nLM, has been described (<nplcit id="ncit0011" status="new" npl-type="s"><text>Gaudino and Paulson (1994) J. Am. Chem. Soc. 116: 1149-1150</text></nplcit>). However, this and other previously available synthetic methods for ganglioside synthesis suffer from low efficiency and other drawbacks. Thus, a need exists for more efficient methods for synthesizing gangliosides. The present invention fulfills this and other needs.</p><heading><b><u style="single">SUMMARY OF THE INVENTION</u></b></heading><p num="p0006">The present invention provides methods for <i>in vitro</i> synthesis of glycosphingoids, including gangliosides, and other oligosaccharide-containing compounds. The methods involve the enzymatic transfer of carbohydrates, including sialic acids, to a sphingoid precursor. In particular, the methods involve contacting the sphingoid precursor with one or more glycosyltransferases and the corresponding sugar donor moiety for the glycosyltransferases, and other reactants required for glycosyltransferase activity, for a sufficient time and under appropriate conditions to transfer the sugar or sugars from the donor moiety to the sphingoid precursor. In some embodiments, one or more of the<!-- EPO <DP n="3"> --> enzymatic reactions is carried out in the presence of an organic solvent, which increases the efficiency of the glycosylation reaction. Another way to increase the efficiency of the reaction is to use a glycosyltransferase cycle to generate the nucleotide sugar donor moiety. The enzymatic step is typically preceded by hydrolysis of the fatty acid moiety from the ceramide; a fatty acid moiety can be reattached after completion of the glycosyltransferase reaction. As much as 100% efficiency is obtainable using the methods of the invention.</p><p num="p0007">In one embodiment, the invention provides methods for adding one or more sialic acid residues to a glycosylated ceramide to form a ganglioside. The glycosylated ceramide is contacted with a sialyltransferase and a sialic acid donor moiety and other reactants required for sialyltransferase activity, under conditions such that sialic acid is transferred from the sialic acid donor moiety to the saccharide moiety of the glycosylated ceramide.</p><p num="p0008">Accordingly, some embodiments of the invention provide methods of enzymatically synthesizing a glycosphingoid that involve contacting a sphingoid with a glycosyltransferase reaction mixture that includes: a) one or more glycosyltransferases, b) a corresponding nucleotide sugar for each glycosyltransferase, and c) other reactants required for glycosyltransferase activity. The reaction mixture is incubated for a sufficient time and under appropriate conditions to transfer the sugar or sugars from the nucleotide sugar to the sphingoid to form a glycosylated sphingoid. The methods include at least one efficiency enhancing step selected from the group consisting of including an organic solvent in the glycosyltransferase reaction mixture, and using a glycosyltransferase cycle to generate the nucleotide sugar. If further enhancement of efficiency is desired, the fatty acid can be removed form the sphingoid prior to the glycosyltransferase reaction.</p><p num="p0009">In additional embodiments, the methods of the invention further involve contacting the glycosylated sphingoid that is produced in the first reaction mixture with a second glycosyltransferase reaction mixture that includes: a) an additional glycosyltransferase, b) a corresponding nucleotide sugar for the additional glycosyltransferase, and c) other reactants required for activity of the additional glycosyltransferase. The reaction mixture is incubated for a sufficient time and under appropriate conditions to transfer the sugar from the nucleotide sugar to the glycosylated sphingoid.<!-- EPO <DP n="4"> --></p><heading><b><u style="single">BRIEF DESCRIPTION OF THE DRAWINGS</u></b></heading><p num="p0010"><ul list-style="bullet"><li>Figure 1 shows a schematic diagram of two methods for synthesis of the ganglioside GM<sub>2</sub> by enzymatic synthesis using as the starting material lactosylceramide obtained from bovine buttermilk.</li><li>Figure 2 shows a schematic diagram of two methods for synthesizing the ganglioside GD<sub>2</sub> from lactosylceramide obtained from bovine buttermilk.</li><li>Figure 3 shows three routes for synthesizing a GM2 ganglioside using a plant glucosylceramide as the starting material.</li><li>Figure 4 shows three routes for synthesizing GM2 and other gangliosides starting from a glucosylceramide.</li><li>Figure 5 shows a scheme used for synthesis of the ganglioside GM2 from lactosylceramide via deacylation, two consecutive enzymatic glycosylations, and final chemical acylation.</li></ul></p><heading><b><u style="single">DETAILED DESCRIPTION</u></b></heading><heading><b><u style="single">Definitions</u></b></heading><p num="p0011">The following abbreviations are used herein:
<dl id="dl0001" compact="compact"><dt>Ara</dt><dd>= arabinosyl;</dd><dt>Fru</dt><dd>= fructosyl;</dd><dt>Fuc</dt><dd>= fucosyl;</dd><dt>Gal</dt><dd>= galactosyl;</dd><dt>GalNAc</dt><dd>= N-acetylgalactosaminyl;</dd><dt>Glc</dt><dd>= glucosyl;</dd><dt>GlcNAc</dt><dd>= N-acetylglucosaminyl;</dd><dt>Man</dt><dd>= mannosyl; and</dd><dt>NeuAc</dt><dd>= sialyl (typically N-acetylneuraminyl).</dd></dl></p><p num="p0012">Oligosaccharides are considered to have a reducing end and a non-reducing end, whether or not the saccharide at the reducing end is in fact a reducing sugar. In accordance with accepted nomenclature, oligosaccharides are depicted herein with the non-reducing end on the left and the reducing end on the right. All oligosaccharides described herein are described with the name or abbreviation for the non-reducing saccharide (<i>e.g.</i>, Gal), followed by the configuration of the glycosidic bond (α or β), the ring bond, the ring<!-- EPO <DP n="5"> --> position of the reducing saccharide involved in the bond, and then the name or abbreviation of the reducing saccharide (<i>e.g.</i>, GlcNAc). The linkage between two sugars may be expressed, for example, as 2,3, 2→3, 2-3, or (2,3). Each saccharide is a pyranose.</p><p num="p0013">A "sphingoid," as used herein, includes sphingosines, phytosphingosines, sphinganines, ceramides, and the like. Both naturally occurring and synthetically produced compounds are included.</p><p num="p0014">A "glycosphingolipid" is a carbohydrate-containing derivative of a sphingoid or ceramide. The carbohydrate residue is attached by a glycosidic linkage to O-1 of the sphingoid.</p><p num="p0015">The term "sialic acid" (abbreviated "Sia") refers to any member of a family of nine-carbon carboxylated sugars. The most common member of the sialic acid family is N-acetyl-neuraminic acid (2-keto-5-acetamindo-3,5-dideoxy-D-glycero-D-galactononulopyranos-1-onic acid (often abbreviated as Neu5Ac, NeuAc, or NANA). A second member of the family is N-glycolyl-neuraminic acid (Neu5Gc or NeuGc), in which the N-acetyl group ofNeuAc is hydroxylated. A third sialic acid family member is 2-keto-3-deoxy-nonulosonic acid (KDN) (<nplcit id="ncit0012" status="new" npl-type="s"><text>Nadano et al. (1986) J. Biol. Chem. 261: 11550-11557</text></nplcit>; <nplcit id="ncit0013" status="new" npl-type="s"><text>Kanamori et al. (1990) J. Biol. Chem. 265: 21811-21819</text></nplcit>. Also included are 9-substituted sialic acids such as a 9-O-C<sub>1</sub>-C<sub>6</sub> acyl-Neu5Ac like 9-O-lactyl-Neu5Ac or 9-O-acetyl-Neu5Ac, 9-deoxy-9-fluoro-Neu5Ac and 9-azido-9-deoxy-Neu5Ac. For review of the sialic acid family, <i>see, e.g.,</i><nplcit id="ncit0014" status="new" npl-type="s"><text>Varki (1992) Glycobiology 2: 25-40</text></nplcit>; <nplcit id="ncit0015" status="new" npl-type="b"><text>Sialic Acids: Chemistry, Metabolism and Function, R. Schauer, Ed. (Springer-Verlag, New York (1992</text></nplcit>). The synthesis and use of sialic acid compounds in a sialylation procedure is described in, for example, <patcit id="pcit0003" dnum="WO9216640A" status="new"><text>international application WO 92/16640, published October 1, 1992</text></patcit>.</p><p num="p0016">The term "isolated" is meant to refer to material which is substantially or essentially free from components which normally accompany the material as found in its native state. Thus, in some embodiments, the gangliosides and other glycosphingoids made using the methods of the invention do not include materials normally associated with <i>in situ</i> environment of these compounds. Typically, isolated glycoconjugates of the invention are at least about 80% pure, usually at least about 90%, and preferably at least about 95% pure as measured by band intensity on a silver stained gel or other method for determining purity. Purity or homogeneity can be indicated by a number of means well known in the art, such as are described below.<!-- EPO <DP n="6"> --></p><heading><b><u style="single">Description of the Preferred Embodiments</u></b></heading><p num="p0017">The present invention provides methods for efficient synthesis of glycolipids, including gangliosides, glycosphingoids, and other glycosylated structures. For example, the invention provides methods for synthesizing gangliosides that are useful for study of ganglioside biological function, as well as for therapeutic applications. The methods involve contacting a glycosylated or unglycosylated ceramide or sphingoid with a glycosyltransferase and a sugar donor moiety for a sufficient time and under appropriate reaction conditions to transfer the sugar from the donor moiety to the ceramide or sphingoid. In some embodiments, the enzymatic reaction is carried out in the presence of an organic solvent which can increase the efficiency of the reaction. In other presently preferred embodiments, the fatty acid moiety is removed from the ceramide or sphingoid prior to the glycosyltransferase reaction, thus further increasing the effectiveness of the enzymatic transfer.</p><heading><b><i>A. Enzymatic Synthesis of Glycoceramide- and Sphingoid-Associated Oligosaccharides</i></b></heading><p num="p0018">The invention provides methods of adding one or more saccharide moieties in a specific manner in order to obtain a desired ganglioside or other glycosphingolipid. The methods of the invention involve the use of one or more glycosyltransferases to synthesize glycosphingoids, including gangliosides and other glycosphingoids. Through use of a glycosyltransferase to link a desired carbohydrate to the precursor molecule, one can achieve a desired linkage with high specificity. In presently preferred embodiments, the methods of the invention involve the removal of the fatty acid moiety from the sphingoid precursor prior to the glycosyltransferase reaction, and/or the use of an organic solvent to facilitate the reaction.</p><p num="p0019">The choice of glycosyltransferase(s) used in a given synthesis method of the invention will depend upon the acceptor which is used as the starting material and the desired end product. A method can involve the use of more than one glycosyltransferase, where more than one saccharide is to be added. The multiple glycosyltransferase reactions can be carried out simultaneously or sequentially. To obtain sufficient amounts of glycosyltransferase for large-scale reaction, a nucleic acid that encodes the enzyme can be cloned and expressed as a recombinant soluble enzyme by methods known to one of ordinary skill in the art.<!-- EPO <DP n="7"> --></p> <p num="p0020">In some embodiments, the invention allows one to synthesize a glycosphingolipid starting from a ceramide or other non-glycosylated sphingoid. The initial enzyme involved in synthesis of a glycoceramide from a ceramide precursor is, depending on the desired end product, either a ceramide glucosyltransferase (EC 2.4.1.80, for glucosylceramide) or a ceramide galactosyltransferase (EC 2.4.1.45, for galactosylceramide) (Step 1). For review of glycosphingolipid biosynthesis, <i>see</i>, <i>e.g.,</i><nplcit id="ncit0016" status="new" npl-type="s"><text>Ichikawa and Hirabayashi (1998) Trends Cell Biol. 8:198-202</text></nplcit>. Accordingly, when the methods of the invention are used to synthesize a glycosphingolipid using a non-glycosylated ceramide or sphingoid as the starting material, the reaction mixture will include one of these enzymes. Ceramide glucosyltransferases are available from various sources. For example, the human nucleotide sequence is known (GenBank Accession No. D50840; <nplcit id="ncit0017" status="new" npl-type="s"><text>Ichikawa et al. (1996) Proc. Nat'l. Acad. Sci. USA 93:4638-4643</text></nplcit>), so one can use recombinant methods to obtain the enzyme. The nucleotide sequence of the human ceramide galactosyltransferase also has been reported (GenBank Accession No. U62899; <nplcit id="ncit0018" status="new" npl-type="s"><text>Kapitonov and Yu (1997) Biochem. Biophys. Res. Commun. 232: 449-453</text></nplcit>), and thus the enzyme is easily obtainable. The acceptor used in these reactions can be any of N-acylsphingosine, sphingosine and dihydrosphingosine. Suitable donor nucleotide sugars for the glycosyltransferase include UDP-Glc and CDP-Glc, while the galactosyltransferase typically uses UDP-Gal as a donor.</p> <p num="p0021">In other embodiments, an acceptor saccharide for a sialyltransferase or other glycosyltransferase is present on the precursor molecule to be modified upon <i>in vivo</i> synthesis of the precursor. For example, one can use as the starting material a glycosylceramide or other glycosphingoid. Such glycosphingoids can be sialylated or otherwise glycosylated using the methods of the invention to add additional saccharide residues to those that are already present on the precursor. In some embodiments, the additional saccharide residues are added without prior modification of the glycosylation pattern of the glycosphingolipid starting material. Alternatively, the invention provides methods of altering the glycosylation pattern of a glycosphingolipid prior to adding the additional saccharide residues. If the starting glycosphingolipid does not provide a suitable acceptor for the glycosyltransferase which catalyzes a desired saccharide addition, one can modify the glycosphingolipid to include an acceptor by methods known to those of skill in the art. For example, to provide a suitable acceptor for a sialyltransferase, a suitable acceptor can be synthesized by using a galactosyltransferase to attach a galactose residue to, for<!-- EPO <DP n="8"> --> example, a GalNAc or other appropriate saccharide moiety that is linked to the glycosphingoid. In other embodiments, glycosphingoid-linked oligosaccharides can be first "trimmed," either in whole or in part, to expose either an acceptor for the sialyltransferase or a moiety to which one or more appropriate residues can be added to obtain a suitable acceptor. Enzymes such as glycosyltransferases and endoglycosidases are useful for the attaching and trimming reactions.</p> <p num="p0022">The second step in the synthesis of gangliosides involves the addition of a second carbohydrate residue, galactose, to the glucosylsphingoid to form the structure Galβ1-4Glc-R, wherein R is ceramide (and the product is lactosylceramide) or other sphingoid (Step 2). This reaction is catalyzed by a UDP-Gal: glucosylceramide β-1,4-galactosyltransferase (EC 2.4.1.38), which is also referred to as lactosylceramide synthase. This enzyme has been characterized from rat (<nplcit id="ncit0019" status="new" npl-type="s"><text>Nomura et al. (1998) J. Biol. Chem. 273: 13570-7</text> </nplcit>), and nucleotide sequences are available for the corresponding cDNA of chicken (GenBank Accession Nos. U19890 and U19889) and mouse (GenBank Accession No. L16840; <nplcit id="ncit0020" status="new" npl-type="s"><text>Shaper et al. (1988) J. Biol. Chem. 263: 10420-10428</text></nplcit>).</p><p num="p0023">In an alternative embodiment, the galactosylation is carried out using a β-galactosidase. The glycosphingoid precursor is contacted β-galactosidase and a compound having the formula Gal-X, where X is a leaving group attached to the 1-position of the galactose residue, under conditions suitable for transfer of the Gal residue from the Gal-X to the glucosylceramide. Suitable leaving groups include, for example, β-p-nibrophenyl, phenyl, methyl, methoxymethyl, and methoxyethyl ethers. Other activating groups are discussed in, for example, Nilsson <i>et al.</i> (1988) <i>Trends Biotechnol.</i> 6: 256, and citations therein. The use of galactosidases for adding a galactose to a saccharide is described in, for example, <patcit id="pcit0004" dnum="US5403726A" status="new"><text>US Patent Nos. 5,403,726</text></patcit> and <patcit id="pcit0005" dnum="US5374541A" status="new"><text>5,374,541</text></patcit>.</p><p num="p0024">The glycosyltransferase used to add the next saccharide moiety (Step 3) will depend on the particular glycosphingolipid to be synthesized. In one embodiment, the invention provides methods of adding one or more sialic acid residues to a glycosylceramide to form a ganglioside. These methods make use of sialyltransferases, which comprise a family of glycosyltransferases that transfer sialic acid from the donor substrate CMP-sialic acid to acceptor oligosaccharide substrates. At least 15 different mammalian sialyltransferases have been documented, and the cDNAs of thirteen of these have been cloned to date (for the systematic nomenclature that is used herein, <i>see,</i> Tsuji <i>et al.</i> (1996)<!-- EPO <DP n="9"> --><i>Glycobiology</i> 6: v-xiv). In addition, two bacterial sialyltransferases have been recently reported (<nplcit id="ncit0021" status="new" npl-type="s"><text>Yamamoto et al. (1996) J. Biochem. 120: 104-110</text></nplcit>; <nplcit id="ncit0022" status="new" npl-type="s"><text>Gilbert et al. (1996) J. Biol. Chem. 271: 28271-28276</text></nplcit>).</p><p num="p0025">An acceptor for the sialyltransferase will be present on the glycosylceramide to be modified by the methods of the present invention. Suitable acceptors, include, for example, galactosyl acceptors such as Galβ1,4GalNAc-, Galβ1,3GalNAc-, lacto-N-tetraose-, Galβ1,3GlcNAc-, Galβ1,4GlcNAc-, Galβ1,3Ara-, Galβ1,6GlcNAc-, and Galβ1,4Glc-(lactose). Other acceptors known to those of skill in the art (<i>see, e.g.,</i><nplcit id="ncit0023" status="new" npl-type="s"><text>Paulson et al. (1978) J. Biol. Chem. 253: 5617-5624</text></nplcit>). Typically, the acceptors form part of an oligosaccharide chain that is attached to a ceramide or other glycosphingoid moiety.</p><p num="p0026">The particular sialyltransferase employed in the reactions will depend upon the ganglioside being synthesized. For the ganglioside GM3, for example, an α2,3 sialyltransferase is used, along with its acceptor CMP-sialic acid. A suitable enzyme for this reaction is described in <nplcit id="ncit0024" status="new" npl-type="s"><text>Ishii (1997) Glycoconj. J. 14(supp. 1): S49</text></nplcit>.</p><p num="p0027">Additional gangliosides can be synthesized by contacting α2,3-sialylated moieties with an α2,8-sialyltransferase, either after or simultaneously with the α2,3 sialyltransferase reaction. The α2,8-sialyltransferase catalyzes the addition of a sialic acid residue linked α2,8 to the α2-3-linked sialic acid. By this method, one can synthesize the gangliosides GD1a, GD1b, GT1a, GT1b, GT1c, and GQ1b, for example. The structures for these gangliosides, as well as those discussed above, are shown in Table 2. For example, to synthesize the ganglioside GD3, an α2,8 sialyltransferase is used, either simultaneously with or after the reaction with a α2,3 sialyltransferase. A suitable enzyme for this reaction is the ST8Sia I (GD3/GT3 synthase; EC 2.4.99.8; <i>see, e.g.,</i> (human) <nplcit id="ncit0025" status="new" npl-type="s"><text>Nara et al. (1994) Proc. Natl. Acad. Sci. USA 91: 7952-7956</text></nplcit>; <nplcit id="ncit0026" status="new" npl-type="s"><text>Haraguchi et al. (1994) Proc. Natl. Acad. Sci. USA 91:10455-10459</text></nplcit>; <nplcit id="ncit0027" status="new" npl-type="s"><text>Sasaki et al. (1994) J. Biol. Chem. 269:15950-15956</text></nplcit>; <nplcit id="ncit0028" status="new" npl-type="s"><text>Nakayama et al. (1996) J. Biol. Chem. 271:3684-3691</text></nplcit>) and mouse (<nplcit id="ncit0029" status="new" npl-type="s"><text>Yoshida et al. (1995) J. Biol. Chem. 270:14628-14633</text></nplcit>)), which links a sialic acid residue in an α2-8 linkage to a previously added α2-3-linked sialic acid. Another sialyltransferase, ST8GalNAcIII can be used to convert GM1 to GD1. The rat cDNA for this enzyme has been cloned and characterized (<nplcit id="ncit0030" status="new" npl-type="s"><text>Sjoberg et al. (1996) J. Biol. Chem. 271:7450-7459</text></nplcit>; GenBank Accession No. L29554). Other α2-8-sialylatransferases include ST8SiaII, STX (<nplcit id="ncit0031" status="new" npl-type="s"><text>Scheidegger et al. (1995) J. Biol. Chem. 270: 22685-22688</text></nplcit>) and ST8SiaIII, which utilizes Sia2,3Gal1,4GlcNAc as an<!-- EPO <DP n="10"> --> acceptor, and thus is useful in methods for synthesizing neolactogangliosides <i>(</i><nplcit id="ncit0032" status="new" npl-type="s"><text>Yoshida et al. (1995) J. Biol. Chem. 270: 14628-14633</text></nplcit>). In a presently preferred embodiment, the-two sialyltransferase reactions are carried out simultaneously.</p><p num="p0028">For sialylation of the lacto- and neolacto- series of gangliosides, the sialyltransferase will be able to transfer sialic acid to the structures Galβ1,4GlcNAc- and Galβ1,4GlcNAc-, respectively. Suitable sialyltransferases include those that are summarized in Table 1.
<tables id="tabl0001" num="0001"><table frame="bottom"><title><b>Table 1: Sialyltransferases which use the Galβ1,4GlcNAc sequence as an acceptor substrate.</b></title><tgroup cols="4" colsep="0"><colspec colwidth="38mm" colnum="1" colname="col1"/><colspec colwidth="34mm" colnum="2" colname="col2"/><colspec colwidth="51mm" colnum="3" colname="col3"/><colspec colwidth="19mm" colnum="4" colname="col4"/><thead><row><entry align="center" valign="top"><b>Sialyltransferase</b></entry><entry align="center" valign="top"><b>Source</b></entry><entry align="center" valign="top"><b>Sequence(s) formed</b></entry><entry align="center" valign="top"><b>Ref.</b></entry></row></thead><tbody><row><entry align="center">ST6Gal I</entry><entry align="center">Mammalian</entry><entry>NeuAcα2,6Galβ1,4GlcNAc-</entry><entry align="center">1</entry></row><row><entry align="center">ST3Gal III</entry><entry align="center">Mammalian</entry><entry>NeuAcα2,3Galβ1,4GlcNAc-</entry><entry align="center">1</entry></row><row><entry align="center"/><entry align="center"/><entry>NeuAcα2,3Galβ1,3GlcNAc-</entry><entry align="center"/></row><row><entry align="center">ST3Gal IV</entry><entry align="center">Mammalian</entry><entry>NeuAcα2,3Galβ1,4GlcNAc-</entry><entry align="center">1</entry></row><row><entry align="center"/><entry align="center"/><entry>NeuAcα2,3Galβ1,3 GlcNAc-</entry><entry align="center"/></row><row><entry align="center">ST6Gal II</entry><entry align="center">photobacterium</entry><entry>NeuAcα2,6Galβ1,4GlcNAc-</entry><entry align="center">2</entry></row><row><entry align="center">ST3Gal V</entry><entry align="center"><i>N. meningitides</i></entry><entry>NeuAcα2,3Galβ1,4GlcNAc-</entry><entry align="center">3</entry></row><row><entry align="center"/><entry align="center"><i>N. gonorrhoeae</i></entry><entry/><entry align="center"/></row></tbody></tgroup><tgroup cols="4" rowsep="0"><colspec colwidth="38mm" colnum="1" colname="col1"/><colspec colwidth="34mm" colnum="2" colname="col2"/><colspec colwidth="51mm" colnum="3" colname="col3"/><colspec colwidth="19mm" colnum="4" colname="col4"/><tbody><row><entry nameend="col4" align="justify" namest="col1">1) <nplcit id="ncit0033" status="new" npl-type="s"><text>Goochee et al. (1991) Bio/Technology 9: 1347-1355</text></nplcit>

2) <nplcit id="ncit0034" status="new" npl-type="s"><text>Yamamoto et al. (1996) J. Biochem. 120: 104-110</text></nplcit>

3) <nplcit id="ncit0035" status="new" npl-type="s"><text>Gilbert et al. (1996) J Biol. Chem. 271: 28271-28276</text></nplcit></entry></row></tbody></tgroup></table></tables></p><p num="p0029">In addition to serving as a substrate for sialyltransferases, the lactosylceramide can also be utilized as the acceptor for a β1,4-galactosaminyltransferase (EC 2.4.1.92), which catalyzes the transfer of a GalNAc from UDP-GalNAc to the Gal moiety of the lactosylceramide. The nucleotide sequence for this enzyme is available for human (GenBank Accession No. M83651; <nplcit id="ncit0036" status="new" npl-type="s"><text>Nagata et al. (1992) J. Biol. Chem. 267: 12082-12087</text></nplcit>), rat (GenBank Accession No. D17809;<nplcit id="ncit0037" status="new" npl-type="s"><text>Hidari et al. (1994) Biochem. J. 301: 957-965</text></nplcit>), and mouse (GenBank Accession No. L25885; <nplcit id="ncit0038" status="new" npl-type="s"><text>Sango et al. (1995) Genomics 27: 362-365</text></nplcit>), for example. Therefore, the enzyme is readily obtainable by recombinant methods.</p><p num="p0030">To synthesize the ganglioside GM2 from the resulting GalNAcβ4Galβ4GlcCer moiety, an α2,3 sialyltransferase is employed, as discussed above. The ganglioside GD2<!-- EPO <DP n="11"> --> can be synthesized by the methods of the invention by use of an α2,8 sialyltransferase following, or simultaneously with, the reaction with the α2,3 sialyltransferase. Alternatively, an α2,6 sialyltransferase (ST6GalNAcI; EC 2.4.99.3) can be employed to add a sialic acid residue in an α2,6 linkage (<nplcit id="ncit0039" status="new" npl-type="s"><text>Kurosawa et al. (1994) J. Biol. Chem. 269: 1402-1409</text></nplcit>).</p><p num="p0031">The GalNAcβ4Galβ4Glc-Cer moiety can also be used as the acceptor for synthesis of additional glycosphingolipids. For example, the invention provides methods in which this compound is galactosylated using a β1,3 galactosyltransferase. A suitable galactosyltransferase for this application is described in, for example, <nplcit id="ncit0040" status="new"  npl-type="s"><text>Ghosh et al. (1995) Glycoconj. J. 12: 838-47</text></nplcit>.</p><p num="p0032">To synthesize the gangliosides GM1a and GM1b from the resulting Galβ3GalNAcβ4Galβ4Glc-Cer moiety, the methods of the invention involve contacting the moiety with an α2,3 sialyltransferase. For example, the methods can use a ST3Gal III sialyltransferase (human: <nplcit id="ncit0041" status="new" npl-type="s"><text>Sasaki et al. (1993) J. Biol. Chem. 268: 22782-22787</text></nplcit>; GenBank Accession No. x74570). The bacterial sialyltransferases are also suitable for this reaction (Table 1).</p><p num="p0033">The invention also provides methods of adding sialic acid in an α2,6Gal linkage. For example, the use of ST6Gal I can catalyze the addition of a sialic acid in an α2,6Gal linkage. This enzyme is commercially available (Boehringer Mannheim Biochemicals, Indianapolis IN), and the cDNA has been cloned from several organisms, including rat (<nplcit id="ncit0042" status="new" npl-type="s"><text>Weinstein et al. (1987) J. Biol. Chem. 262: 17735-17743</text></nplcit>), human (<nplcit id="ncit0043"  status="new"  npl-type="s"><text>Grundmann et al. (1990) Nucl. Acids Res. 18:667</text></nplcit>; <patcit id="pcit0006"  dnum="EP0475354A" status="new"><text>Zettlmeisl et al. (1992) Patent EP 0475354</text></patcit>; <nplcit id="ncit0044" status="new" npl-type="s"><text>Stamenkovic et al. (1990) J. Exp. Med. 172:641-643</text></nplcit>, <nplcit id="ncit0045" status="new" npl-type="s"><text>Bast et al. (1992) J. Cell Biol. 116:423-435</text></nplcit>), mouse (<nplcit id="ncit0046" status="new" npl-type="s"><text>Hamamoto et al. (1993) Bioorg. Med. Chem. 1:141-145</text></nplcit>), and chicken (<nplcit id="ncit0047" status="new" npl-type="s"><text>Kurosawa et al. (1994) Eur. J. Biochem. 219:375-381</text></nplcit>). Other gangliosides can be synthesized using ST6GalNAcII, which adds an α2,6-linked sialic acid to the Galβ3GalNAc-moiety (chicken, <nplcit id="ncit0048" status="new" npl-type="s"><text>Kurosawa et al. (1994) J. Biol. Chem. 269: 19048-19053</text></nplcit>, GenBank Accession No. x77775).</p><p num="p0034">The sialyltransferases and other glycosyltransferases can be used either alone or in conjunction with additional enzymes. For example, Figure 2 shows a schematic diagram of two pathways for synthesis of the ganglioside GD<sub>2</sub> starting from lactosylceramide. Each pathway involves the use of two different sialyltransferases (an α2,3ST and an α2,8ST), as well as a GalNAc transferase. In the preferred pathway, the fatty<!-- EPO <DP n="12"> --> acid is removed from the lactosylceramide by treatment with base (Step 1). Acetylation is then performed (Step 2), after which a sialic acid is attached to the galactose residue in an α2,3 linkage by an α2,3 sialyltransferase (Step 3). The sialylation steps are performed, preferably in the presence of an organic solvent as described herein, thereby driving the reaction nearly to completion. A GalNAc residue is then added to the galactose in a β1,4 linkage using a GalNAc transferase (Step 5). Finally, a fatty acid is added, <i>e.g.</i>, by reaction with steroyl chloride, to complete the ganglioside (Step 6).</p><p num="p0035">One of skill in the art, using the guidance provided herein, can choose additional glycosyltransferases, alone or in combination, that can catalyze the synthesis of other glycosphingolipids of interest. For example, to synthesize a lacto- or neolactoglycosphingolipid, one would replace the β1,4 galactosaminyltransferase in Step 3 above with a β1,3GlcNAc transferase. Contacting the product of this reaction with a β1,3 galactosyltransferase (lacto) or a β1,4 galactosyltransferase (neolacto) will then provide the acceptor for the appropriate sialyltransferase or sialyltransferases to synthesize a ganglioside, as desired. An example of a sialyltransferase that is useful in these methods is ST3Gal III, which is also referred to as α(2,3)sialyltransferase (EC 2.4.99.6). This enzyme catalyzes the transfer of sialic acid to the Gal of a Galβ1,3GlcNAc or Galβ1,4GlcNAc glycoside (<i>see, e.g.,</i><nplcit id="ncit0049" status="new" npl-type="s"><text>Wen et al. (1992) J. Biol. Chem., 267: 21011-21019</text></nplcit>; <nplcit id="ncit0050" status="new" npl-type="s"><text>Van den Eijnden et al. (1991) J. Biol. Chem., 256: 3159</text></nplcit>). The sialic acid is linked to a Gal with the formation of an α-linkage between the two saccharides. Bonding (linkage) between the saccharides is between the 2-position of NeuAc and the 3-position of Gal. This particular enzyme can be isolated from rat liver (<nplcit id="ncit0051" status="new" npl-type="s"><text>Weinstein et al. (1982) J. Biol. Chem., 257: 13845</text></nplcit>); the human cDNA (<nplcit id="ncit0052" status="new" npl-type="s"><text>Sasaki et al. (1993) J. Biol. Chem. 268:22782-22787</text></nplcit>; <nplcit id="ncit0053" status="new" npl-type="s"><text>Kitagawa &amp; Paulson (1994) J. Biol. Chem. 269:1394-1401</text></nplcit>) and genomic (<nplcit id="ncit0054" status="new" npl-type="s"><text>Kitagawa et al. (1996) J. Biol. Chem. 271:931-938</text></nplcit>) DNA sequences are known, facilitating production of this enzyme by recombinant expression. In one embodiment, the methods of the invention use a rat ST3Gal III.</p><p num="p0036">Similarly, one can synthesize the globo- and isoglobo-glycosphingolipids by replacing the β1,4-galactosaminyltransferase in Step 3 above with an α1,4- (globo) or an α1,3-galactosyltransferase (isoglobo). The products of these reactions are subjected to β1,3GalNAc transferase-catalyzed addition of a GalNAc residue to the nonreducing Gal residue. Again, treatment of the product with one or more sialyltransferases will yield a desired ganglioside.<!-- EPO <DP n="13"> --></p><p num="p0037">Gangliosides and other glycosphingolipids sometimes include other sugars in addition to those described above. For example, fucose residues are sometimes present. Accordingly, the invention provides methods of synthesizing these fucosylated glycosphingolipids. These methods involve the use of a fucosyltransferase to catalyze the transfer of a fucose residue from an activated nucleotide sugar (GDP-fucose) to an appropriate acceptor. For example, one can contact a GM1a ganglioside with an α1,2-fucosyltransferase to obtain a ganglioside having the structure Fucα2Galβ3GalNAcβ4 (Siaα3)Galβ4Glc-Cer (<nplcit id="ncit0055" status="new" npl-type="s"><text>Wiegandt (1973) H.-S. Zschr. Physiol. Chem. 354: 1049-1056</text></nplcit>).</p><p num="p0038">The methods of the invention are useful for producing any of a large number of gangliosides and related structures. Many gangliosides of interest are described in <nplcit id="ncit0056" status="new" npl-type="b"><text>Oettgen, H.F., ed., Gangliosides and Cancer, VCH, Germany, 1989, pp. 10-15</text></nplcit>, and references cited therein. Gangliosides of particular interest include, for example, those found in the brain as well as other sources which are listed in Table 2.
<tables id="tabl0002" num="0002"><table frame="bottom"><title><b>Table 2: Ganglioside Formulas and Abbreviations</b></title><tgroup cols="2" colsep="0"><colspec colwidth="93mm" colnum="1" colname="col1"/><colspec colwidth="25mm" colnum="2" colname="col2"/><thead><row><entry align="center" valign="top"><b>Structure</b></entry><entry align="center" valign="top"><b>Abbreviation</b></entry></row></thead><tbody><row><entry>Neu5Ac3Gal4GlcCer</entry><entry align="center">GM3</entry></row><row><entry>GalNAc4(Neu5Ac3)Gal4GlcCer</entry><entry align="center">GM2</entry></row><row><entry>Gal3GalNAc4(Neu5Ac3)Gal4GlcCer</entry><entry align="center">GM1a</entry></row><row><entry>Neu5Ac3Gal3GalNAc4Gal4GlcCer</entry><entry align="center">GM1b</entry></row><row><entry>Neu5Ac8Neu5Ac3Gal4GlcCer</entry><entry align="center">GD3</entry></row><row><entry>GalNAc4(Neu5Ac8Neu5Ac3)Gal4GlcCer</entry><entry align="center">GD2</entry></row><row><entry>Neu5Ac3Gal3GalNAc4(Neu5Ac3)Gal4GlcCer</entry><entry align="center">GD1a</entry></row><row><entry>Neu5Ac3Gal3(Neu5Ac6)GalNAc4Gal4GlcCer</entry><entry align="center">GD1α</entry></row><row><entry>Gal3GalNAc4(Neu5Ac8Neu5Ac3)Gal4GlcCer</entry><entry align="center">GD1b</entry></row><row><entry>Neu5Ac8Neu5Ac3Ga!3Ga!NAc4(Neu5Ac3)Gal4GlcCer</entry><entry align="center">GT1a</entry></row><row><entry>Neu5Ac3Gal3GalNAc4(Neu5Ac8Neu5Ac3)Gal4GlcCer</entry><entry align="center">GT1b</entry></row><row><entry>Gal3GalNAc4(Neu5Ac8Neu5Ac8Neu5Ac3)Gal4GlcCer</entry><entry align="center">GT1c</entry></row><row><entry>Neu5Ac8Neu5Ac3Gal3GalNAc4(Neu5Ac8Neu5c3)Gal4GlcCer</entry><entry align="center">GQ1b</entry></row></tbody></tgroup><tgroup cols="2" rowsep="0"><colspec colwidth="93mm" colnum="1" colname="col1"/><colspec colwidth="25mm" colnum="2" colname="col2"/><tbody><row><entry nameend="col2" align="justify" namest="col1"><i>Nomenclature of Glycolipids,</i> IUPAC-IUB Joint Commission on Biochemical Nomenclature (Recommendations 1997); <nplcit id="ncit0057" status="new" npl-type="s"><text>Pure Appl. Chem. (1997) 69: 2475-2487</text></nplcit>; <nplcit id="ncit0058" status="new" npl-type="s"><text>Eur. J. Biochem (1998) 257: 293-298</text></nplcit>) (www.chem.qmw.ac.uk/iupac/misc/glylp.html).</entry></row></tbody></tgroup></table></tables><!-- EPO <DP n="14"> --></p><p num="p0039">In some embodiments, the invention provides methods for <i>in vitro</i> sialylation of saccharide groups present on a glycosylceramide, wherein the methods first involve modifying the glycosylceramide to create a suitable acceptor. A preferred method for synthesizing an acceptor involves use of a galactosyltransferase. The steps for these methods include:
<ol><li>(a) galactosylating a compound of the formula Glcβ-OR with a galactosyltransferase in the presence of a UDP-galactose under conditions sufficient to form the compound: Galβ(1-4)Glcβ-OR; and</li><li>(b) sialylating the compound formed in (a) with a sialyltransferase in the presence of a CMP derivative of a sialic acid using a α(2,3)sialyltransferase under conditions in which sialic acid is transferred to the non-reducing sugar to form the compound NeuAcα(2-3)Galβ(1-4)Glc-β-OR. In this formula, R is a ceramide or sphingoid. In some embodiments, this product is contacted with an α2,8-sialyltransferase under conditions in which a sialic acid residue is transferred to the α2,3-linked sialic acid to form the compound NeuAcα(2-8)NeuAcα(2-3)Galβ(1-4)Glc-β-OR.

In additional embodiments, the Galβ(1-4)Glcβ-OR compound formed in step (a) is further modified, either before or after the sialylation step (b). For example, the methods can involve the additional steps of:</li><li>(c) adding a GaINAc residue to Galβ(1-4)Glcβ-OR by contacting the compound with a β1,4-galactosaminyltransferase in the presence of UDP-GalNAc under conditions in which GalNAc is transferred to the non-reducing end of the oligosaccharide to form GalNAcβ(1-4) Galβ(1-4)Glcβ-OR; and</li><li>(d) adding a Gal residue to GalNAcβ(1-4) Galβ(1-4)Glcβ-OR by contacting the compound formed in step (c) with a β1-3-galactosyltransferase in the presence of UDP-Gal, under conditions in which Gal is transferred to the non-reducing end of the oligosaccharide to form Galβ(1-3)GalNAcβ(1-4) Galβ(1-4)Glcβ-OR.

Further embodiments of the invention involve synthesis of gangliosides by:</li><li>(e) contacting the product of step (d) with one or more sialyltransferases as described in step (b), under conditions in which sialic acid is transferred to either or both of the Gal residues. This reaction can involve, for example, an α2-3-sialyltransferase alone, or an α2-3-sialyltransferase and an α2,8-sialyltransferase.</li></ol><!-- EPO <DP n="15"> --></p><p num="p0040">The sphingoids that can be used as starting materials in the methods of the invention include, but are not limited to, those that have the formula I:
<chemistry id="chem0001" num="0001"><img id="ib0001" orientation="unknown" wi="55" img-format="tif" img-content="chem" file="imgb0001.tif" inline="no" he="30"/></chemistry>
wherein R<sup>1</sup> is selected from the group consisting of H, Glcβ1-, Galβ1-, and lactoseβ1-;

R<sup>2</sup> is selected from the group consisting of CH<sub>2</sub> and
<chemistry id="chem0002" num="0002"><img id="ib0002" orientation="unknown" wi="18" img-format="tif" img-content="chem" file="imgb0002.tif" inline="no" he="13"/></chemistry>
R<sup>3</sup> is selected from the group consisting of H, CH<sub>3</sub>, CH<sub>2</sub>CH<sub>3</sub>,
<chemistry id="chem0003" num="0003"><img id="ib0003" orientation="unknown" wi="37" img-format="tif" img-content="chem" file="imgb0003.tif" inline="no" he="19"/></chemistry>
R<sup>4</sup> is selected from the group consisting of:
<ul list-style="bullet"><li>(i) C<sub>2</sub>-C<sub>36</sub> saturated, unsaturated, or polyunsaturated alkyl;</li><li>(ii) α-hydroxy-C<sub>2</sub>-C<sub>36</sub> alkyl;</li><li>(iii) ω-hydroxy-C<sub>2</sub>-C<sub>36</sub> alkyl;</li><li>(iv) α,ω-dihydroxy-C<sub>2</sub>-C<sub>36</sub> alkyl;</li><li>(v) ClCH<sub>2</sub>-, Cl<sub>2</sub>CH-, or Cl<sub>3</sub>C-; and</li><li>(vi) an alkanoyl group having the formula
<chemistry id="chem0004" num="0004"><img id="ib0004" orientation="unknown" wi="30" img-format="tif" img-content="chem" file="imgb0004.tif" inline="no" he="14"/></chemistry>
in which R<sup>6</sup> is either a divalent C<sub>2</sub>-C<sub>36</sub> alkyl or a divalent α-hydroxy- C<sub>2</sub>-C<sub>36</sub> alkyl, and R<sup>7</sup> is either a monovalent C<sub>2</sub>-C<sub>36</sub> alkyl or a monovalent α-hydroxy- C<sub>2</sub>-C<sub>36</sub> alkyl; and</li></ul>
R<sup>5</sup> is selected from the group consisting of a saturated, unsaturated, or polyunsaturated C<sub>2</sub>-C<sub>37</sub> alkyl group.</p><p num="p0041">In some embodiments, the sphingoids comprise the formula II:<!-- EPO <DP n="16"> --><chemistry id="chem0005" num="0005"><img id="ib0005" orientation="unknown" wi="54" img-format="tif" img-content="chem" file="imgb0005.tif" inline="no" he="24"/></chemistry>
wherein R<sup>1</sup> is selected from the group consisting of H, Glcβ1-, Galβ1-, lactoseβ1-, and an oligosaccharide;

R<sup>2</sup> is selected from the group consisting of H, a saturated or unsaturated C<sub>2</sub>-C<sub>26</sub> alkyl group, and a protecting group; and

R<sup>3</sup> is a saturated, unsaturated, or polyunsaturated C<sub>2</sub>-C<sub>37</sub> alkyl group, or a protecting group.</p><p num="p0042">Thus, the invention provides methods of synthesizing glycosphingoids having the formula III:
<chemistry id="chem0006" num="0006"><img id="ib0006" orientation="unknown" wi="51" img-format="tif" img-content="chem" file="imgb0006.tif" inline="no" he="19"/></chemistry>
wherein X<sup>1</sup> is a sphingoid, such as a ceramide or a sphingosine, for example;

X<sup>2</sup> and X<sup>4</sup> are each independently selected from the group consisting of -H, Siaα2-3-, Siaα2-6-, Siaα2-8-Siaα2-3-, and Fucα1-2-;

X<sup>3</sup> is optional and, if present, is selected from the group consisting of GalNAcβ1-4-, Galβ1-3GalNAcβ1-4-, Fucα1-2Galβ1-3GalNAcβ1-4-, Galβ1-3GlcNAcβ1-3-, Galβ1-4GlcNAcβ1-3-, GalNAcβ1-3Galα1-4-, and GalNAcβ1-3Galα1-3-.</p><p num="p0043">In one embodiment, the sphingoid is Neu5Ac3Gal4GlcCer, the glycosyltransferase is a β1,4-GalNAc transferase, and the nucleotide sugar is UDP-GalNAc and the product is GalNAc4Neu5Ac3Gal4GlcCer. The Neu5Ac3Gal4GlcCer is produced using a method that comprises contacting Gal4GlcCer with an α2,3-sialyltransferase and CMP-Neu5Ac, or can be obtained by other means. Similarly, the Gal4GlcCer can be produced using a method that comprises contacting GlcCer with a β1,4-galactosyltransferase and UDP-Gal, or can be otherwise obtained. In additional embodiments, the sphingoid is Neu5Ac8Neu5Ac3GalcGCer, the glycosyltransferase is a β1,4-GalNAc transferase, the nucleotide sugar is UDP-GalNAc and the product is GalNAc4(Neu5Ac8Neu5Ac3) Gal4GlcCer.</p><p num="p0044">The invention also provides a method of enzymatically synthesizing a ganglioside that involves:<!-- EPO <DP n="17"> --><ul list-style="bullet"><li>(a) contacting a compound of the formula Glcβ-OR with a β1,4-galactosyltransferase in the presence of UDP-galactose under conditions sufficient to transfer galactose from the UDP-galactose to form a compound having the formula Galβ(1-4)Glcβ-OR; and</li><li>(b) contacting the compound formed in (a) with an α2,3-sialyltransferase in the presence of CMP-sialic acid under conditions sufficient to transfer sialic acid from the CMP-sialic acid to form a compound having the formula Siaα(2-3)Galβ(1-4)Glc-β-OR;</li></ul>
wherein R is a sphingoid. Sphingoids can include, for example, sphingosines, phytosphingosines, sphinganines, and ceramides.</p><p num="p0045">The methods of the invention involve performing at least one efficiency enhancing step selected from the group consisting of: a) including an organic solvent in the glycosyltransferase reaction mixture; and b) using a glycosyltransferase cycle to generate the either or both of the UDP-galactose and the CMP-sialic acid. In presently preferred embodiments, the fatty acid is removed from the sphingoid prior to the galactosyltransferase reaction, and the same or a different fatty acid is attached to the product of the glycosyltransferase reactions.</p><p num="p0046">In additional embodiments, the methods further involve contacting the compound formed in step (a) or the compound formed in step (b) with a β1,4-galactosaminyltransferase in the presence of UDP-GalNAc under conditions in which GalNAc is transferred to form a compound having a formula GalNAcβ(1-4)Galβ(1-4)Glcβ-OR or GalNAcβ(1-4)(Siaα(2-3))Galβ(1-4)Glcβ-OR, respectively.</p><p num="p0047">The methods can further involve contacting the compound having the formula GalNAcβ(1-4)Galβ(1-4)Glcβ-OR or GalNAcβ(1-4)(Siaα(2-3))Galβ(1-4)Glcβ-OR with a β1,3-galactosyltransferase in the presence of UDP-Gal, under conditions in which Gal is transferred to form a galactosyl compound having a formula Galβ(1-3)GalNAcβ(1-4)Galβ(1-4)Glcβ-OR or Galβ(1-3)GalNAcβ(1-4)(Siaα(2-3))Galβ(1-4)Glcβ-OR.</p><p num="p0048">In some embodiments, the method further involve contacting the galactosyl compound with an α2,3-sialyltransferase in the presence of CMP-sialic acid under conditions sufficient to transfer sialic acid from the CMP-sialic acid to form a sialylated compound having a formula selected from the group consisting of Siaα(2,3)Galβ(1-3)GalNAcβ(1-4)Galβ(1-4)Glcβ-OR and Siaα(2,3)Galβ(1-3)GalNAcβ(1-4)(Siaα(2-3))Galβ(1-4)Glcβ-OR.<!-- EPO <DP n="18"> --> The sialylated compound can be contacted with an α2,8-sialyltransferase and CMP-sialic acid under conditions in which a sialic acid residue is transferred from the CMP-sialic acid to form a compound having a formula selected from the group consisting of:
<ul list-style="bullet"><li>Siaα(2,8)Siaα(2,3)Galβ(1-3)GalNAcβ(1-4)Galβ(1-4)Glcβ-OR;</li><li>Siaα(2,8)Siaα(2,3)Galβ(1-3)GalNAcβ(1-4)(Siaα(2-3))Galβ(1-4)Glcβ-OR;</li><li>Siaα(2,8)Siaα(2,3)Galβ(1-3)GalNAcβ(1-4)(Siaα(2-3))Galβ(1-4)Glcβ-OR;</li><li>Siaα(2,3)Galβ(1-3)GalNAcβ(1-4)(Siaα(2,8)Siaα(2-3))Galβ(1-4)Glcβ-OR; and</li><li>Siaα(2,8)Siaα(2,3)Galβ(1-3)GalNAcβ(1-4)(Siaα(2,8)Siaα(2-3))Galβ(1-4)Glcβ-OR.</li></ul></p><p num="p0049">In other embodiments, the invention provides methods of enzymatically synthesizing disialylgangliosides. These methods can involve contacting a compound having the formula Siaα(2-3)Galβ(1-4)Glc-β-OR with an α2,8-sialyltransferase and CMP-sialic acid under conditions in which a sialic acid residue is transferred from the CMP-sialic acid to form a compound having the formula Siacα(2-8)Siaα(2-3)Galβ(1-4)Glc-β-OR. Additional saccharide residues can be added to this compound by, for example, contacting the compound having the formula Siaα(2-8)Siaα(2-3)Galβ(1-4)Glc-β-OR with a β1,4-galactosaminyltransferase in the presence of UDP-GalNAc under conditions in which GalNAc is transferred to form a compound having a formula GalNAcβ(1-4)(Siaα(2-8)Siα(2-3))Galβ(1-4)Glcβ-OR.</p><p num="p0050">In additional embodiments, these methods of the invention further involve contacting the compound having the formula GalNAcβ(1-4)(Siaα(2-8)Siaα(2-3))Galβ(1-4)Glcβ-OR with a β1,3-galactosyltransferase in the presence of UDP-Gal, under conditions in which Gal is transferred to form a galactosyl compound having a formula Galβ(1-3)GalNAcβ(1-4)(Siaα(2-8)Siaα(2-3))Galβ(1-4)Glcβ-OR. This compound can be sialylated by contacting the galactosyl compound with an α2,3-sialyltransferase in the presence of CMP-sialic acid under conditions sufficient to transfer sialic acid from the CMP-sialic acid to form a sialylated compound having a formula Siaα(2-3)Galβ(1-3)GalNAcβ(1-4)(Siaα(2-8)Siaα(2-3))Galβ(1-4)Glcβ-OR. If desired, an additional sialic acid can be added by<!-- EPO <DP n="19"> --> contacting the sialylated compound with an α2,8-sialyltransferase and CMP-sialic acid under conditions in which a sialic acid residue is transferred from the CMP-sialic acid to form a compound having a formula Siaα(2-8)Siaα(2-3)Galβ(1-3)GalNAcβ(1-4)(Siaα(2-8)Siaα(2-3))Galβ(1-4)Glcβ-OR.</p><p num="p0051">The invention also provides methods of producing lacto- and neolacto- compounds. These methods can involve contacting Galβ(1-4)Glcβ-OR or Siaα(2-3)Galβ(1-4)Glc-β-OR with a β1,3-glucosaminyltransferase in the presence of UDP-GlcNAc under conditions in which GlcNAc is transferred to form a compound having a formula GlcNAcbβ(1-4)Galβ(1-4)Glcβ-OR or GlcNAcβ(1-4)(Siaα(2-3))Galβ(1-4)Glcβ-OR, respectively. These products can in turn be contacted with a β1,3-galactosyltransferase (for lacto) or a β1,4-galactosyltransferase (for neolacto) in the presence of UDP-Gal, under conditions in which Gal is transferred to form a galactosyl compound having a formula selected from the group consisting of:
<ul list-style="bullet"><li>Galβ(3(1-3)GlcNAcβ(1-4)Galβ(1-4)Glcβ-OR (lacto);</li><li>Galβ(1-4)GlcNAcβ(1-4)Galβ(1-4)Glcβ-OR (neolacto);</li><li>Galβ(1-3)GlcNAcβ(1-4)(Siaα(2-3))Galβ(1-4)Glcβ-OR (lacto); and</li><li>Galβ(1-4)GlcNAcβ(1-4)(Siaα(2-3))Galβ(1-4)Glcβ-OR (neolacto).</li></ul></p><p num="p0052">In additional embodiments, these products are sialylated by contacting the galactosyl compound with an α2,3-sialyltransferase in the presence of CMP-sialic acid under conditions sufficient to transfer sialic acid from the CMP-sialic acid to form a sialylated compound having a formula selected from the group consisting of:
<ul list-style="bullet"><li>Siaα(2-3)Galβ(1-3)GlcNAcp(1-4)Galβ(1-4)Glcβ-OR;</li><li>Siaα(2-3)Galβ(1-4)GlcNAcp(1 -4)Galβ(1-4)Glcβ-OR;</li><li>Siaα(2-3)Galβ(1-3)GlcNAcβ(1-4)(Siaα(2-3))Galβ(1-4)Glcβ-OR; and</li><li>Siaα(2-3)Galβ(1-4)GlcNAcβ(1-4)(Siaα(2-3))Galβ(1-4)Glcβ-OR</li></ul></p><p num="p0053">These sialylated compounds can in turn be contacted with an α2,8-sialyltransferase and CMP-sialic acid under conditions in which a sialic acid residue is transferred from the CMP-sialic acid to form a compound having a formula selected from the group consisting of:
<ul list-style="bullet"><li>Siaα(2-8)Siaα(2-3)Galβ(1-3)GlcNAcβ(1-4)Galβ3(1-4)Glcβ-OR;</li><li>Siaα(2-8)Siaα(2-3)Galβ(1-4)GlcNAcβ(1-4)Galβ(1-4)Glcβ-OR;<!-- EPO <DP n="20"> --></li><li>Siaα(2-3)Galβ(1-3)GlcNAcβ(1-4)(Siaα(2-8)Siaα(2-3))Galβ(1-4)Glcβ-OR;</li><li>Siaα(2-3)Galβ(1-4)GlcNAcβ(1-4)(Siaα(2-8)Siaα(2-3))Galβ(1-4)Glcβ-OR;</li><li>Siaα(2-8)Siaα(2-3)Galβ(1-3)GlcNAcβ(1-4)(Siaα(2-3))Galβ(1-4)Glcβ-OR; and</li><li>Siaα(2-8)Siaα(2-3)Galβ(1-4)GlcNAcβ(1-4)(Siaα(2-3))Galβ(1-4)Glcβ-OR.</li></ul></p><p num="p0054">Sphingoids of particular interest include, for example, sphingosines, phytosphingosines, sphinganines, and ceramides. The sphingoids can be naturally occurring or can be produced synthetically or semisynthetically. An example of a semisynthetically produced ganglioside derivative that one can produce using the methods of the invention is the N-dichloroacetylsphingosine compounds described in <nplcit id="ncit0059" status="new" npl-type="s"><text>Kharlamov et al. (1994) Proc. Nat'l. Acad. Sci. USA 91: 6303-6307</text></nplcit> (<i>e.g.</i>, LIGA20) and Schneider <i>et al.</i> (1994) <i>Neurology</i> 44: 748, in which R<sup>2</sup> in the above formula II includes the lipid moiety 2-dichloroacetylamide. In some embodiments, the dicloroacetylsphingosine compounds have R<sup>3</sup> in formula II as being 4-<i>trans</i>-octadecene.</p><p num="p0055">The present invention also provides methods of synthesizing analogs of gangliosides and other glycosphingolipids. For example, one can use glycosyltransferases as described above, except that an analog of a sugar is attached to the activated nucleotide which serves as the saccharide donor. The analog is chosen so that the analog-nucleotide is still capable of serving as a donor for the glycosyltransferase of interest. Examples of suitable analogs for use in synthesizing gangliosides are described in, for example, <patcit id="pcit0007" dnum="US5352670A" status="new"><text>US Patent No. 5,352,670</text></patcit>.</p><heading><b><i>B. Removal of Fatty Acids</i></b></heading><p num="p0056">In some embodiments, the methods of the invention involve removal of a fatty acid moiety from a glycoceramide or sphingoid prior to reaction with the glycosyltransferase. Methods of removing a fatty acid moiety from a glycosphingolipid are known to those of skill in the art. Standard carbohydrate and glycosphingolipid chemistry methodology can be employed, such as that described in, for example, <nplcit id="ncit0060" status="new" npl-type="s"><text>Paulson et al. (1985) Carbohydrate Res. 137: 39-62</text></nplcit>; <nplcit id="ncit0061" status="new" npl-type="s"><text>Beith-Halahmi et al. (1967) Carbohydrate Res. 5: 25-30</text></nplcit>;<!-- EPO <DP n="21"> --><nplcit id="ncit0062" status="new" npl-type="s"><text>Alais and Veyrieries (1990) Carbohydrate Res. 207: 11-31</text></nplcit>; <nplcit id="ncit0063" status="new" npl-type="s"><text>Grudler and Schmidt, (1985) Carbohydrate Res. 135: 203-218</text></nplcit>; <nplcit id="ncit0064" status="new" npl-type="s"><text>Ponpipom et al. (1978) Tetrahedron Lett. 1717-1720</text></nplcit>; <nplcit id="ncit0065" status="new" npl-type="s"><text>Murase et al. (1989) Carbohydrate Res. 188: 71-80</text></nplcit>; <nplcit id="ncit0066" status="new" npl-type="s"><text>Kameyama et al. (1989) Carbohydrate Res. 193: c1-c5</text></nplcit>; <nplcit id="ncit0067" status="new" npl-type="s"><text>Hasegawa et al. (1991) J. Carbohydrate Chem. 10: 439-459</text></nplcit>; <nplcit id="ncit0068" status="new" npl-type="s"><text>Schwarzmann and Sandhoff (1987) Meth. Enzymol. 138: 319-341</text></nplcit>; <nplcit id="ncit0069" status="new" npl-type="s"><text>Guadino and Paulson (1994) J. Am. Chem. Soc. 116: 1149-1150</text></nplcit> (including supplemental material, which is also incorporated herein by reference). For example, hydrolysis of the fatty acid moiety can be effected by base hydrolysis.</p><p num="p0057">Once the glycosylation reactions are completed, one can attach the same or a different fatty acid to the product of the glycosylation reactions. Methods for coupling a fatty acid are known to those of skill in the art.</p><heading><b><i>C. Use of Organic Solvents</i></b></heading><p num="p0058">In some embodiments, the glycosyltransferase reactions are carried out in the presence of an organic solvent. In presently preferred embodiments, the fatty acid moiety is first hydrolyzed as described above. The enzymatic catalyses can be carried out in the presence of an organic solvent, such as, for example, methanol, ethanol, dimethylsulfoxide, isopropanol, tetrahydrofuran, chloroform, and the like, either singly or in combination. The proportion of the organic solvent in the reaction mixture is typically at least about 3%, more preferably at least about 5%, and most preferably at least about 8%. The reaction mixture typically contains about 25% or less of organic solvent, more preferably about 20% or less, and most preferably about 10% or less organic solvent. In a presently preferred embodiment, the reaction mixture contains about 8-10% methanol.</p><p num="p0059">The use of an organic solvent in the reaction mixture provides several advantages over previously described enzymatic synthesis methods of glycosylceramides. A previously known method for synthesis of the neolacto series ganglioside 6'-nLM, was completed with less than 5% yield based on sialic acid (<nplcit id="ncit0070" status="new" npl-type="s"><text>Hasegawa et al. (1991) J. Carbohydrate Chem. 10: 439-459</text></nplcit>). A subsequently reported method which involved removal of the fatty acid in conjunction with the presence of a detergent in the reaction mixture obtained a yield of only 30-40% (Guadino and Paulson, <i>supra.</i>). The use of an organic solvent as provided by the present invention not only results in a much higher yield than was obtainable previously, it also eliminates the need for a detergent to increase<!-- EPO <DP n="22"> --> accessibility to the glycosyl moiety of the glycosylceramide. This facilitates purification of the resulting ganglioside. However, detergents can also be used in the methods of the invention.</p><heading><b><i>D. Glycosyltransferase Reaction Conditions</i></b></heading><p num="p0060">The glycosylation steps in the methods of the invention are preferably carried out enzymatically. In a preferred embodiment, a plurality of enzymatic steps are carried out in a single reaction mixture that contains two or more different glycosyltransferases. For example, one can conduct a galactosylating and a sialylating step simultaneously by including both sialyltransferase and galactosyltransferase in the reaction mixture. In this embodiment, the enzymes and substrates can be combined in an initial reaction mixture, or preferably the enzymes and reagents for a second glycosyltransferase cycle can be added to the reaction medium once the first glycosyltransferase cycle has neared completion. By conducting two glycosyltransferase cycles in sequence in a single vessel, overall yields are improved over procedures in which an intermediate species is isolated. Moreover, cleanup and disposal of extra solvents and by-products is reduced.</p><p num="p0061">Enzyme amounts or concentrations are expressed in activity Units, which is a measure of the initial rate of catalysis. One activity Unit catalyzes the formation of 1 µmol of product per minute at a given temperature (typically 37°C) and pH value (typically 7.5). Thus, 10 Units of an enzyme is a catalytic amount of that enzyme where 10 µmols of substrate are converted to 10 µmol of product in one minute at a temperature of 37°C and a pH value of 7.5. The enzymes can be utilized free in solution or can be bound to a support such as a polymer. The reaction mixture is thus substantially homogeneous at the beginning, although some precipitate can form during the reaction.</p><p num="p0062">The glycosylation reactions include, in addition to the appropriate glycosyltransferase and acceptor, an activated nucleotide sugar that acts as a sugar donor for the glycosyltransferase. The reactions can also include other ingredients that facilitate glycosyltransferase activity. These ingredients can include a divalent cation (<i>e.g.</i>, Mg<sup>+2</sup> or Mn<sup>+2</sup>), materials necessary for ATP regeneration, phosphate ions, and organic solvents. The concentrations or amounts of the various reactants used in the processes depend upon numerous factors including reaction conditions such as temperature and pH value, and the choice and amount of acceptor saccharides to be glycosylated. The reaction medium may<!-- EPO <DP n="23"> --> also comprise solubilizing detergents (<i>e.g.</i>, Triton or SDS) and organic solvents such as methanol or ethanol, if necessary.</p><p num="p0063">In optimized reactions, the above ingredients can be combined by admixture in an aqueous reaction medium (solution) which has a pH value of about 6 to about 8.5. The medium is devoid of chelators that bind enzyme cofactors such as Mg<sup>+2</sup> or Mn<sup>+2</sup>. The selection of a medium is based on the ability of the medium to maintain pH value at the desired level. Thus, in some embodiments, the medium is buffered to a pH value of about 7.5, preferably with HEPES. If a buffer is not used, the pH of the medium should be maintained at about 6 to 8.5, preferably about 7.2 to 7.8, by the addition of base. A suitable base is NaOH, preferably 6 M NaOH.</p><p num="p0064">The temperature at which an above process is carried out can range from just above freezing to the temperature at which the most sensitive enzyme denatures. That temperature range is preferably about zero degrees C to about 110°C, and more preferably at about 20°C to about 30°C, or higher for a thermophilic organism.</p><p num="p0065">The reaction mixture so formed is maintained for a period of time sufficient for the glycosyltransferase(s) to glycosylate a high percentage of the acceptors. Some of the product can often be detected after a few hours, with recoverable amounts usually being obtained within 24 hours. For commercial-scale preparations, the reaction will often be allowed to proceed for about 8-240 hours, with a time of between about 24 and 48 hours more typical.</p><p num="p0066">In some presently preferred embodiments, the glycosylation steps are carried out using a half-cycle or full cycle in which one or more reaction components are regenerated. Glycosyltransferase cycles and half-cycles are described in <patcit id="pcit0008" dnum="US5728554A" status="new"><text>US Patent No. 5,728,554</text></patcit>. For example, the galactosylating step can be carried out as part of a galactosyltransferase cycle and the sialylating step is preferably carried out as part of a sialyltransferase cycle. Preferred conditions and descriptions of other species and enzymes in each of these, and other, cycles have been described. <i>See, e.g.,</i> commonly assigned <patcit id="pcit0009" dnum="US60071076B" status="new"><text>US Provisional Application No. 60/071,076, filed January 15, 1998</text></patcit> and <patcit id="pcit0010" dnum="US08628543B" status="new"><text>US Patent Application No. 08/628,543, filed April 10, 1996</text></patcit>.</p><p num="p0067">As an example, the sialylation of the glycosylceramide can be accomplished using a sialyltransferase cycle, which includes a CMP-sialic acid recycling system that utilizes CMP-sialic acid synthetase. CMP-sialic acid is relatively expensive, so <i>in situ</i><!-- EPO <DP n="24"> --> synthesis of this sialic acid donor moiety enhances the economic advantages provided by the claimed methods. Sialyltransferase cycles are described, for example, in <patcit id="pcit0011" dnum="US5374541A" status="new"><text>US Patent No. 5,374,541</text></patcit>. The CMP-sialic acid regenerating system used in this embodiment comprises cytidine monophosphate (CMP), a nucleoside triphosphate, a phosphate donor, a kinase capable of transferring phosphate from the phosphate donor to nucleoside diphosphates and a nucleoside monophosphate kinase capable of transferring the terminal phosphate from a nucleoside triphosphate to CMP.</p><p num="p0068">The regenerating system also employs CMP-sialic acid synthetase, which transfers sialic acid to CMP. CMP-sialic acid synthetase can be isolated and purified from cells and tissues containing the synthetase enzyme by procedures well known in the art. <i>See,</i> for example, <nplcit id="ncit0071" status="new" npl-type="s"><text>Gross et al. (1987) Eur. J Biochem., 168: 595</text></nplcit>; <nplcit id="ncit0072" status="new" npl-type="s"><text>Vijay et al. (1975) J. Biol. Chem. 250: 164</text></nplcit>; <nplcit id="ncit0073" status="new" npl-type="s"><text>Zapata et al. (1989) J. Biol. Chem. 264: 14769</text></nplcit>; and <nplcit id="ncit0074" status="new" npl-type="s"><text>Higa et al. (1985) J. Biol. Chem. 260: 8838</text></nplcit>. The gene for this enzyme has also been sequenced. See, <nplcit id="ncit0075" status="new" npl-type="s"><text>Vann et al. (1987) J. Biol. Chem., 262:17556</text></nplcit>. Overexpression of the gene has been reported for use in a gram scale synthesis of CMP-NeuAc. <i>See,</i><nplcit id="ncit0076" status="new" npl-type="s"><text>Shames et al. (1991) Glycobiology, 1:187</text></nplcit>. This enzyme is also commercially available.</p><p num="p0069">Nucleoside triphosphates suitable for use in accordance with the CMP-sialic acid regenerating system are adenosine triphosphate (ATP), cytidine triphosphate (CTP), uridine triphosphate (UTP), guanosine triphosphate (GTP), inosine triphosphate (ITP) and thymidine triphosphate (TTP). A preferred nucleoside triphosphate is ATP.</p><p num="p0070">Nucleoside monophosphate kinases are enzymes that catalyze the phosphorylation of nucleoside monophosphates. Nucleoside monophosphate kinase (NMK) or myokinase (MK; EC 2.7.4.3) used in accordance with the CMP-sialic acid regenerating system of the present invention are used to catalyze the phosphorylation of CMP. NMK's are commercially available (Sigma Chem. Co., St. Louis, Mo; Boehringer Mannheim, Indianapolis, Ind.).</p><p num="p0071">A phosphate donor and a catalytic amount of a kinase that catalyzes the transfer of phosphate from the phosphate donor to an activating nucleotide are also part of the CMP-sialic acid regenerating system. The phosphate donor of the regenerating system is a phosphorylated compound, the phosphate group of which can be used to phosphorylate the nucleoside phosphate. The only limitation on the selection of a phosphate donor is that neither the phosphorylated nor the dephosphorylated forms of the phosphate donor can<!-- EPO <DP n="25"> --> substantially interfere with any of the reactions involved in the formation of the sialylated galactosyl glycoside. Preferred phosphate donors are phosphoenolpyruvate (PEP) and acetyl phosphate. A particularly preferred phosphate donor is PEP.</p><p num="p0072">The selection of a particular kinase for use in a sialic acid cycle depends upon the phosphate donor employed. When acetyl phosphate is used as the phosphate donor, the kinase is acetyl kinase. When PEP is used as the phosphate donor, the kinase is pyruvate kinase (PK; EC 2.7.1.40). Other kinases can be employed with other phosphate donors as is well known to those of skill in the art. Kinases are commercially available (Sigma Chem. Co., St. Louis, Mo.; Boehringer Mannheim, Indianapolis, Ind.).</p><p num="p0073">Because of the self-contained and cyclic character of this glycosylation method, once all the reactants and enzymes are present, the reaction continues until the first of the stoichiometric substrates (<i>e.g.</i> free Neu5Ac and PEP) is consumed.</p><p num="p0074">In the sialylation cycle, CMP is converted to CDP by nucleoside monophosphate kinase in the presence of added ATP. ATP is catalytically regenerated from its byproduct, ADP, by pyruvate kinase (PK) in the presence of added phosphoenolpyruvate (PEP). CDP is further converted to CTP, which conversion is catalyzed by PK in the presence of PEP. CTP reacts with sialic acid to form inorganic pyrophosphate (PPi) and CMP-sialic acid, the latter reaction being catalyzed by CMP-sialic acid synthetase. Following sialylation of the galactosyl glycoside, the released CMP re-enters the regenerating system to reform CDP, CTP and CMP-sialic acid. The formed PPi is scavenged as discussed below, and forms inorganic phosphate (Pi) as a byproduct. Pyruvate is also a byproduct.</p><p num="p0075">The byproduct pyruvate can also be made use of in another reaction in which N-acetylmannosamine (ManNAc) and pyruvate are reacted in the presence of NeuAc aldolase (EC 4.1.3.3) to form sialic acid. Thus, the sialic acid can be replaced by ManNAc and a catalytic amount of NeuAc aldolase. Although NeuAc aldolase also catalyzes the reverse reaction (NeuAc to ManNAc and pyruvate), the produced NeuAc is irreversibly incorporated into the reaction cycle via CMP-NeuAc catalyzed by CMP-sialic acid synthetase coupled with inorganic pyrophosphatase (PPase)-catalyzed decomposition of the released inorganic pyrophosphate. This enzymatic synthesis of sialic acid and its 9-substituted derivatives and the use of a resulting sialic acid in a different sialylating reaction scheme is disclosed in <patcit id="pcit0012" dnum="WO9216640A" status="new"><text>International application WO 92/16640, published on Oct. 1, 1992</text></patcit>.<!-- EPO <DP n="26"> --></p><p num="p0076">As used herein, the term "pyrophosphate scavenger" refers to substances that serve to remove inorganic pyrophosphate from a reaction mixture of the present invention. Inorganic pyrophosphate (PPi) is a byproduct of the preparation of CMP-Neu5Ac. Produced PPi can feed back to inhibit other enzymes such that glycosylation is reduced. However, PPi can be degraded enzymatically or by physical means such as sequestration by a PPi binding substance. Preferably, PPi is removed by hydrolysis using inorganic pyrophosphatase (PPase; EC 3.6.1.1), a commercially available PPi catabolic enzyme (Sigma Chem. Co., St. Louis, Mo.; Boehringer Mannheim, Indianapolis, Ind.), and that or a similar enzyme serves as the pyrophosphate scavenger. One method of removing PPi or Pi from the reaction mixture is to maintain divalent metal cation concentration in the medium. In particular, the cations and the inorganic phosphate produced form a complex of very low solubility. By supplementing the cations which are lost by precipitation with pyrophosphate, the rate of reaction can be maintained and the reactions can be taken to completion (i.e., 100% conversion). Supplementing can be carried out continuously (<i>e.g.</i>, by automation) or discontinuously. When cation concentration is maintained in this way, the transferase reaction cycle can be driven to completion.</p><p num="p0077">For glycosyltransferase cycles, the concentrations or amounts of the various reactants used in the processes depend upon numerous factors including reaction conditions such as temperature and pH value, and the choice and amount of acceptor saccharides to be glycosylated. Because the glycosylation process permits regeneration of activating nucleotides, activated donor sugars and scavenging of produced PPi in the presence of catalytic amounts of the enzymes, the process is limited by the concentrations or amounts of the stoichiometric substrates discussed before. The upper limit for the concentrations of reactants that can be used in accordance with the method of the present invention is determined by the solubility of such reactants. Preferably, the concentrations of activating nucleotides, phosphate donor, the donor sugar and enzymes are selected such that glycosylation proceeds until the acceptor is consumed, thus completely sialylating the saccharide groups present on the glycoprotein.</p><p num="p0078">In some presently preferred embodiments, the glycosylation reactions are conducted by contacting the acceptor with a cell that contains: a) an enzymatic system for producing a nucleotide sugar, and b) a recombinant glycosyltransferase which catalyzes the transfer of a sugar from the nucleotide sugar to the acceptor to produce the desired<!-- EPO <DP n="27"> --> glycosphingoid. The cells are generally permeabilized and added to the reaction mixture. For reactions that require multiple glycosyltransferase steps, one can use cells that contain more than one recombinant glycosyltransferase and produce the corresponding nucleotide sugar for both glycosyltransferases. Mixtures of cell types that each contain one or more glycosyltransferase can be used, or multiple glycosyltransferase systems can be present in one cell type. Suitable methods are described in, for example, commonly assigned patent applications, each entitled "Low Cost Manufacture Of Oligosaccharides", filed on November 18, 1998 as Attorney Docket No. 14137-013800US and on November 19, 1998 as Attorney Docket No. 14137-013810US.</p><p num="p0079">The products produced by the above processes can be used without purification. However, it is usually preferred to recover the product. To purify glycolipids and gangliosides, standard methods for glycolipid preparation can be used (<i>see, e.g.,</i><nplcit id="ncit0077" status="new" npl-type="s"><text>Ledeen et al. (1973) J. Neurochem. 21:829</text></nplcit>). For example, glycolipids can be extracted from a reaction mixture by chloroform/methanol 2:1 and isopropyl alcohol/hexane/water 55:25:20 as described by <nplcit id="ncit0078" status="new" npl-type="s"><text>Kannagi et al. (1982) J. Biol. Chem. 257: 14865</text></nplcit>. The resulting extracts are partitioned by a chloroform/methanol/water (3:2:1) Folch partition. The resulting upper phase of the extraction contains gangliosides and the lower phase contains glycolipids. The upper phase containing gangliosides (glycosphingolipids that contain at least one sialic acid moiety) are isolated and separated into neutral and acidic fractions using DEAE-Sephadex chromatography as described in detail by <nplcit id="ncit0079" status="new" npl-type="s"><text>Ledeen and Yu, Methods Enzymol. 83: 139 (1982</text></nplcit>). The resulting gangliosides are pooled, lyophilized, and dissolved in chloroform/methanol (2:1). The lower phase of the Folch partition contains glycolipids. These are isolated and separated on preparative thin-layer chromatography using chloroform/methanol/water (60:35:8) as the solvent system as described by Symington.</p><p num="p0080">Other standard, well known techniques for recovery of glycosylated saccharides are suitable, including such as thin or thick layer chromatography and ion exchange chromatography. A preferred method of purification involves membrane filtration, more preferably utilizing a reverse osmotic membrane, or one or more column chromatographic techniques for the recovery as is discussed hereinafter and in the literature cited herein. For instance, membrane filtration wherein the membranes have molecular weight cutoff of about 3000 to about 10,000 can be used to remove proteins. Nanofiltration or reverse osmosis can then be used to remove salts and/or purify the soluble oligosaccharide<!-- EPO <DP n="28"> --> products (<i>see, e.g.,</i><patcit id="pcit0013" dnum="US08947775B" status="new"><text>US Patent Application No. 08/947,775, filed October 9, 1997</text></patcit>). Nanofilter membranes are a class of reverse osmosis membranes which pass monovalent salts but retain polyvalent salts and uncharged solutes larger than about 100 to about 700 Daltons, depending upon the membrane used. Thus, in a typical application, saccharides prepared by the methods of the present invention will be retained in the membrane and contaminating salts will pass through.</p><p num="p0081">To identify those gangliosides and glycolipids which contain a desired oligosaccharide, immunochemical glycolipid analysis can be performed according to the procedure of <nplcit id="ncit0080" status="new" npl-type="s"><text>Magnani et al. (1980) Anal. Biochem. 109: 399</text></nplcit>. Briefly, the ganglioside pool described above is chromatographed by thin layer chromatography. The thin layer plate is then incubated with <sup>125</sup>I labeled antibody that binds specifically to the oligosaccharide of interest (<i>e.g.</i>, FH6, which binds specifically to SLX). Following incubation with the labeled antibody, the plate is exposed to radiographic detection film and developed. Black spots on the X-ray film correspond to gangliosides that bind to the monoclonal antibody, and those gangliosides are recovered by scraping the corresponding areas of the silica plate and eluting the gangliosides with chloroform/methanol/water. Glycolipids are also dried and resuspended in chloroform and developed in a similar thin layer system and probed with the radiolabeled antibody.</p><p num="p0082">Other methods by which one can analyze the oligosaccharides produced using the methods of the invention are known to those of skill in the art. For example, the carbohydrate units can be released from the glycosphingoids or glycosylceramides by alkaline β-elimination, for example, and separated from the ceramide or sphingoid moieties by gel filtration. The resulting oligosaccharides are then separated from each other using a combination of gel filtration, HPLC, thin layer chromatography, and ion exchange chromatography, and can be fully analyzed. Complete structural analysis of the purified oligosaccharide units requires the determination of the monosaccharide units, their ring form, configuration (D or L), anomeric linkage (α or β), the positions of the linkages between the sugars and their sequence. In addition, the position of any substituent groups are established. Methylation analysis is used to determine the positions of the glycosidic linkages between the monosaccharides. The anomeric configuration of the sugar residues can be addressed using 500-MHz<sup>1</sup>H NMR spectroscopy. The conditions and methods used to perform a complete structural carbohydrate analysis are described generally in<!-- EPO <DP n="29"> --><nplcit id="ncit0081" status="new" npl-type="b"><text>Beeley, Laboratory Techniques in Biochemistry and Molecular Biology, eds. Burdon and Knippenberg, Elsevier, Amsterdam (1985</text></nplcit>), <nplcit id="ncit0082" status="new" npl-type="s"><text>Hounsell, "Glycoanalysis Protocols", Meth. Mol. Biol. Vol. 76, 1998</text></nplcit>, and <nplcit id="ncit0083" status="new" npl-type="b"><text>El Rassi, Carbohydrate Analysis : High Performance Liquid Chromatography and Capillary Electrophoresis, Elsevier Science Ltd, Vol. 58 (1994</text></nplcit>).</p><p num="p0083">Additional techniques to fully characterize the sugars of an oligosaccharide include FAB-MS (fast atom bombardment-mass spectrometry), HPAE (high pH anion exchange chromatography) and <sup>1</sup>H-NMR. These techniques are complementary. Recent examples of how these techniques are used to fully characterize the structure of an oligosaccharide can be found in the analysis by <nplcit id="ncit0084" status="new" npl-type="s"><text>Spellman et al., (1989) J. Biol. Chem. 264: 14100</text></nplcit>, and <nplcit id="ncit0085" status="new" npl-type="s"><text>Stanley et al. (1988) J. Biol. Chem. 263: 11374</text></nplcit>. Other methods include positive ion fast atom bombardment mass spectroscopy (FAB-MS) and methylation analysis by gas chromatography-electron impact mass spectroscopy (GC/EI-MS) (<i>see,</i><patcit id="pcit0014" dnum="EP89305153A" status="new"><text>EPO Application No. 89305153.2</text></patcit>).</p><heading><b><i>E. Uses for Gangliosides and other Glycosphingoids</i></b></heading><p num="p0084">The gangliosides other compounds that are made using the methods of the invention can be used in a variety of applications, <i>e.g.</i>, as antigens, diagnostic reagents, or as therapeutics. For example, gangliosides have been reported to be useful for treating spinal cord and other nervous system injuries (see, <i>e.g.,</i><nplcit id="ncit0086" status="new" npl-type="s"><text>Skaper et al. (1989) Mol. Neurobiol. 3: 173</text></nplcit>; <nplcit id="ncit0087" status="new" npl-type="s"><text>Samson (1990) Drug Devel. Rev. 19: 209-224</text></nplcit>), stroke, subarachnoid hemorrhage, cognition defects (<nplcit id="ncit0088" status="new" npl-type="s"><text>Kharlamov et al. (1994) Proc. Nat 'l. Acad. Sci. USA 91: 6303-6307</text></nplcit>), Parkinson's disease (<nplcit id="ncit0089" status="new" npl-type="s"><text>Schneider (1998) Ann. N.Y. Acad. Sci. 845: 363-73</text></nplcit>), glutamate neurotoxicity (<nplcit id="ncit0090" status="new" npl-type="b"><text>Costa et al. (1994) In Cirrhosis, Hyperammonemia, and Hepatic Encephalopathy, Grisolin and Felipo, Eds., Plenum Press, NY, 1994, p. 129</text></nplcit>), and other conditions. For review, <i>see, e.g.,</i><nplcit id="ncit0091" status="new" npl-type="s"><text>Nobile-Orazio et al. (1994) Drugs 47: 576-585</text></nplcit>). Gangliosides are involved in the local immunosuppression that is often associated with tumors (<nplcit id="ncit0092" status="new" npl-type="s"><text>Rodden et al. (1991) J. Neurosurg. 74: 606-619</text></nplcit>), so agents that block or disrupt these gangliosides are useful in reducing the inaccessibility of tumors to the immune system. The immunosuppressive effect of gangliosides is useful for, <i>e.g.</i>, suppressing rejection of transplanted organs. Gangliosides are also useful as vaccines against cancer (<i>see, e.g.,</i><patcit id="pcit0015" dnum="US9400757W" status="new"><text>International Application No. PCT/US94/00757</text></patcit> (Publ. No. <patcit id="pcit0016" dnum="WO9416731A" status="new"><text>WO 94/16731</text></patcit>). The inclusion of an adjuvant and/or the use of an antigen delivery system (<i>e.g.</i>, proteosomes, bacterial outer<!-- EPO <DP n="30"> --> membrane proteins, and the like)can enhance the effectiveness of gangliosides as vaccines (Livingston <i>et al.</i> (1993) <i>Vaccine</i> 11: 1199).</p><p num="p0085">Thus, the present invention also provides pharmaceutical compositions which can be used in treating a variety of conditions. The pharmaceutical compositions include the gangliosides or glycosphingoids synthesized using the methods of the invention, along with a pharmaceutically acceptable carrier. Pharmaceutical compositions of the invention are suitable for use in a variety of drug delivery systems. Suitable formulations for use in the present invention are found in <nplcit id="ncit0093" status="new" npl-type="b"><text>Remington's Pharmaceutical Sciences, Mace Publishing Company, Philadelphia, PA, 17th ed. (1985</text></nplcit>). For a brief review of methods for drug delivery, <i>see, e.g.,</i><nplcit id="ncit0094" status="new" npl-type="s"><text>Langer, Science 249:1527-1533 (1990)</text></nplcit>.</p><p num="p0086">The pharmaceutical compositions are intended for parenteral, intranasal, topical, oral or local administration, such as by aerosol or transdermally, for prophylactic and/or therapeutic treatment. Commonly, the pharmaceutical compositions are administered parenterally, <i>e.g.</i>, intravenously. Thus, the invention provides compositions for parenteral administration which comprise the compound dissolved or suspended in an acceptable carrier, preferably an aqueous carrier, <i>e.g.</i>, water, buffered water, saline, PBS and the like. The compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions, such as pH adjusting and buffering agents, tonicity adjusting agents, wetting agents, detergents and the like.</p><p num="p0087">These compositions may be sterilized by conventional sterilization techniques, or may be sterile filtered. The resulting aqueous solutions may be packaged for use as is, or lyophilized, the lyophilized preparation being combined with a sterile aqueous carrier prior to administration. The pH of the preparations typically will be between 3 and 11, more preferably from 5 to 9 and most preferably from 7 and 8.</p><p num="p0088">In some embodiments the gangliosides and other glycosphingoids made using the invention can be incorporated into liposomes formed from standard vesicle-forming lipids. A variety of methods are available for preparing liposomes, as described in, <i>e.g.,</i><nplcit id="ncit0095" status="new" npl-type="s"><text>Szoka et al., Ann. Rev. Biophys. Bioeng. 9:467 (1980</text></nplcit>), <patcit id="pcit0017" dnum="US4235871A" status="new"><text>U.S. Pat. Nos. 4,235,871</text></patcit>, <patcit id="pcit0018" dnum="US4501728A" status="new"><text>4,501,728 </text></patcit>and <patcit id="pcit0019" dnum="US4837028A" status="new"><text>4,837,028</text></patcit>. The targeting of liposomes using a variety of targeting agents (<i>e.g.</i>, the oligosaccharide moieties of the gangliosides of the invention) is well known in the art (<i>see, e.g.,</i><patcit id="pcit0020" dnum="US4957773A" status="new"><text>U.S. Patent Nos. 4,957,773</text></patcit> and <patcit id="pcit0021" dnum="US4603044A" status="new"><text>4,603,044</text></patcit>).<!-- EPO <DP n="31"> --></p><p num="p0089">The compositions containing the gangliosides and other glycosphingoids can be administered for prophylactic and/or therapeutic treatments. In therapeutic applications, compositions are administered to a patient already suffering from a disease, as described above, in an amount sufficient to cure or at least partially arrest the symptoms of the disease and its complications. An amount adequate to accomplish this is defined as a "therapeutically effective dose." Amounts effective for this use will depend on the severity of the disease and the weight and general state of the patient, but generally range from about 0.5 mg to about 40 g of oligosaccharide per day for a 70 kg patient, with dosages of from about 5 mg to about 20 g of the compounds per day being more commonly used.</p><p num="p0090">Single or multiple administrations of the compositions can be carried out with dose levels and pattern being selected by the treating physician. In any event, the pharmaceutical formulations should provide a quantity of the oligosaccharides of this invention sufficient to effectively treat the patient.</p><p num="p0091">The gangliosides and other glycosphingoids may also find use as diagnostic reagents. Diagnostic reagents that contain gangliosides made by the methods of the invention, or moieties that bind to the specific gangliosides (<i>e.g.</i>, lectins and antibodies), are useful in diagnosing several conditions, including, for example, Fabry disease (-Gal--Gal-GalCer), Farber disease (ceramides; N-acylsphingosines), Gaucher disease (glucocerebroside), GM1 gangliosidosis (GM1 ganglioside), metachromatic leukodystrophy (sulfatide; cerebroside sulfate), Sandhoff disease (GM2 ganglioside), Tay-Sachs disease (GM2 ganglioside). For this use, the compounds can be labeled with appropriate labels, including radioisotopes such as, for example, <sup>125</sup>I, <sup>14</sup>C, or tritium.</p><p num="p0092">The gangliosides and other glycosphingoids made using the methods of the invention can be used as an immunogen for the production of monoclonal or polyclonal antibodies specifically reactive with the compounds. The multitude of techniques available to those skilled in the art for production and manipulation of various immunoglobulin molecules can be used in the present invention. Antibodies may be produced by a variety of means well known to those of skill in the art. If desired, the production of antibodies can be enhanced by coupling the ganglioside or other glycosphingolipid to an immunogenic protein (<i>e.g.</i>, KLH) prior to administering the compound to the test animal (<i>see</i>, <patcit id="pcit0022" dnum="US9400757W" status="new"><text>PCT application PCT/US94/00757</text></patcit>, Publ. No. <patcit id="pcit0023" dnum="WO9416731A" status="new"><text>WO 94/16731</text></patcit>). Uses for antibodies against gangliosides and<!-- EPO <DP n="32"> --> other glycosphingolipids include cancer diagnosis and are described in, for example, <patcit id="pcit0024" dnum="US4887931A" status="new"><text>US Patent No. 4,887,931</text></patcit>.</p><p num="p0093">The production of non-human monoclonal antibodies, <i>e.g.</i>, murine, lagomorpha, equine, <i>etc.,</i> is well known and may be accomplished by, for example, immunizing the animal with a preparation containing the oligosaccharide of the invention. Antibody-producing cells obtained from the immunized animals are immortalized and screened, or screened first for the production of the desired antibody and then immortalized. For a discussion of general procedures of monoclonal antibody production, <i>see</i>, <nplcit id="ncit0096" status="new" npl-type="b"><text>Harlow and Lane, Antibodies, A Laboratory Manual Cold Spring Harbor Publications, N.Y. (1988</text></nplcit>).</p><p num="p0094">The following Examples are offered to illustrate, but not to limit, the present invention.</p><heading><b><u style="single">Example 1</u></b></heading><heading><b><u style="single">Sialylation of Lyso-lactosyl ceramide</u></b></heading><p num="p0095">This Example describes the reaction conditions for sialylation of lyso-lactosyl ceramide. Lactosylceramide was obtained from bovine buttermilk and the fatty acid moiety removed by base hydrolysis to form lyso-lactosyl ceramide. A mixture of the lyso-lactosyl ceramide (1.0 mg, 1.6 µmol) and CMP-sialic acid (2.46 mg, 65% purity, 2.40 µmol in HEPES buffer (200 mM, containing 8% MeOH, pH 7.5, 50 µL) was sonicated for twenty minutes. α2,3 sialyltransferase (10 µL, 5U/mL, 50 mU) was then added followed by alkaline phosphatase (1µL, 1.0 x 10<sup>5</sup> U/mL, 100 U). The reaction mixture was kept at room temperature. After one day, a further portion of α2,3-sialyltransferase (10 µL, 5U/mL, 50 mU) was added. After four more days, an additional portion of α2,3-sialyltransferase (10 µL, 5U/mL, 50 mU) was added. After an additional one day at room temperature, thin layer chromatography indicated that the reaction was nearly complete.</p><heading><b><u style="single">Example 2</u></b></heading><heading><b><u style="single">Synthesis of GM2 from Lactosylceramide Obtained From Bovine Buttermilk</u></b></heading><p num="p0096">A schematic diagram of showing two pathways for synthesis of the ganglioside GM<sub>2</sub> from lactosylceramide obtained from bovine buttermilk is shown in Figure<!-- EPO <DP n="33"> --> 1. In the pathway shown at left, the fatty acid is not removed from the lactosylceramide prior to sialylation, and the reaction is not carried out in the presence of an organic solvent. The reaction at right, in contrast, is carried out in the presence of an organic solvent, and with removal of the fatty acid.</p><p num="p0097">First, the fatty acid is hydrolyzed from the lactosylceramide by treatment with a base and water (Step 1). A sialic acid residue is then added by enzymatic transfer to the galactose residue using an α2,3-sialyltransferase, preferably an ST3GalIV (Step 2). This reaction can be carried out in the presence of an organic solvent. A GalNAc residue is then attached to the galactose in a β1,4 linkage using a GalNAc transferase (Step 3); this step may or may not be carried out in the presence of an organic solvent. Finally, the fatty acid moiety is reattached to the sphingosine to obtain the desired GM<sub>2</sub> ganglioside. The reaction typically proceeds nearly to completion due to the presence of an organic solvent during the sialylation.</p><p num="p0098">The efficiency of each step can be monitored by TLC or other analytical methods. A reaction is typically considered complete when greater than 90% yield is obtained.</p><heading><b><u style="single">Example 3</u></b></heading><heading><b><u style="single">Synthesis of Gangliosides from Plant Glucosyl Ceramide</u></b></heading><p num="p0099">This Example describes three alternative procedures for the synthesis of the GM2 ganglioside using plant glucosylceramide as the precursor (Figure 3). In Route 1, β1,4-galactosidase is used to catalyze the transfer of a Gal residue to the glucosylceramide. Simultaneously, an α2,3-sialyltranasferase is used in a sialyltransferase cycle to link a sialic acid residue to the Gal. Next, a β1,4-GalNAc transferase is added to the reaction mixture, either with UDP-GalNAc or as part of a GalNAc transferase cycle. In this step, the GalNAc residue is linked to the Gal residue in an α2,3 linkage.</p><p num="p0100">Route 2 differs from the synthesis shown in Route 1 in that the addition of the Gal to the glycosylceramide is catalyzed by a β1,4-galactosyltransferase enzyme, using either a galactosyltransferase cycle or UDP-Glc/Gal as the acceptor sugar. Sialylation and addition of GalNAc are carried out as described above to obtain GM2.<!-- EPO <DP n="34"> --></p><p num="p0101">In Route 3, the fatty acid is first removed by treatment with aqueous base prior to the glycosyltransferase steps. The galactosylation, sialylation, and GalNAc transferase reactions are carried out as in Route 2. Following the addition of the GalNAc residue, a fatty acid is linked to the molecule. The fatty acid can be the same as that originally found on the plant glucosylceramide, or can be different. In the example shown in Figure 3, an activated C<sub>18</sub> fatty acid is used, resulting in the synthesis of GM2. Greater efficiency is generally observed when the fatty acid is removed prior to the glycosylation reactions.</p><p num="p0102">The efficiency of each step can be monitored by TLC or other analytical methods.</p><heading><b><u style="single">Example 4</u></b></heading><heading><b><u style="single">Synthesis of Ganglioside GM2 from Glycosylceramide</u></b></heading><p num="p0103">This Example describes three alternative procedures for the synthesis of the GM2 and other gangliosides using a glucosylceramide as the precursor (Figure 4). In Route 1, a β1,4-galactosidase is used to catalyze the transfer of a Gal residue to the glycosylceramide. Simultaneously, an α2,3-sialyltranasferase is used in a sialyltransferase cycle to link a sialic acid residue to the Gal. Next, a β1,4-GalNAc transferase is added to the reaction mixture, either with UDP-GalNAc or as part of a GalNAc transferase cycle. In this step, the GalNAc residue is linked to the Gal residue in an α2,3 linkage.</p><p num="p0104">Route 2 differs from the synthesis shown in Route 1 in that the addition of the Gal to the glycosylceramide is catalyzed by a β1,4-galactosyltransferase enzyme, using either a galactosyltransferase cycle or UDP-Glc/Gal as the acceptor sugar. Sialylation and addition of GalNAc are carried out as described above to obtain GM2.</p><p num="p0105">In Route 3, the fatty acid is first removed by treatment with aqueous base prior to the glycosyltransferase steps. The galactosylation, sialylation, and GalNAc transferase reactions are carried out as in Route 2. Following the addition of the GalNAc residue, a fatty acid is linked to the molecule. In the example shown in Figure 4, an activated C<sub>18</sub> fatty acid is used, resulting in the synthesis of GM2. Greater efficiency is generally observed when the fatty acid is removed prior to the glycosylation reactions.<!-- EPO <DP n="35"> --></p><p num="p0106">After each synthetic route, additional glycosyltransferases can be used to add additional saccharide residues in order to obtain more complex gangliosides. The efficiency of each step can be monitored by TLC or other analytical methods.</p><heading><b><u style="single">Example 5</u></b></heading><heading><b><u style="single">Synthesis of GM2 Ganglioside</u></b></heading><p num="p0107">This Example describes the preparation of the ganglioside GM2 from lactosylceramide via deacylation, two consecutive enzymatic glycosylations, and final chemical acylation. This reaction sequence provided GM2 in 30% overall yield. The scheme used for this synthesis is shown in Figure 5.</p><heading><b><u style="single">Methods</u></b></heading><heading><b><i>A. Procedure for the hydrolysis with KOH</i></b></heading><p num="p0108">A mixture of lactosylceramide (100 mg, 0.104 mmol) and KOH (1.12g) in MeOH (20 mL) was heated at 105-110°C in a sealed tube for 24 h. The reaction was then acidified with AcOH and then concentrated. The residue was loaded onto a C-18 column and eluted with methanol and water (50:50 to 10:0) to give the lactosylsphingosine (46 mg, 71 % yield).</p><heading><b><i>B. Procedure for the hydrolysis with hydrazine</i></b></heading><p num="p0109">A mixture of lactosylceramide (100 mg, 0.104 mmol) and hydrazine (5 mL) was heated at 145-155°C in a sealed tube for 24 h. The reaction was then acidified with AcOH and concentrated. The residue was loaded onto a C-18 column and eluted with methanol and water (50:50 to 100:0) to give the lactosylphingosine (41 mg, 63%).</p><heading><b>C. <i>Procedure for the sialyltransferase reaction</i></b></heading><p num="p0110">A mixture of lyso-lactosyl ceramide (38 mg, 0.06 mmol) and CMP-sialic acid (93 mg, 0.0915 mmol) in HEPES buffer (200 mM, containing 8% MeOH, pH 7.5, 2.0 mL) was added to α-2,3 sialyltransferase (0.6 mL, 3U) and alkaline phosphate (400 U). The reaction mixture was kept at room temperature. After one day, a further poriton of α-2,3 sialyltransferase (0.5 U) was added. After 13 days at room temperature, the reaction mixture was located onto a C-18 reverse phase column and eluted with H<sub>2</sub>O and MeOH (100:0 to 0: 100) to give the product (24 mg, 43%).<!-- EPO <DP n="36"> --></p><heading><b><i>D. Procedure for the GalNAc transferase reaction</i></b></heading><p num="p0111">A mixture of sialylated lyso-lactosyl ceramide (1.0 mg, 1.6 µmol) and UDP-GalNAc (2.46 mg, 65% purity, 2.40 µmol) in HEPES buffer (200 mM, containing 8% MeOH, pH 7.5, 50 µL) was sonicated for 20 minutes. β1,4-GalNAc transferase (10 µL, 5 U/mL, 50 U) was added, followed by alkaline phosphatase (1 uL, 1.0 x 10<sup>5</sup> U/mL, 100 U). The reaction mixture was kept at room temperature. After one day, a further portion of β1,4-GalNAc transferase (10 µL, 5 U/mL, 50 U) was added. After 4 more days, an additional portion of β1,4-GalNAc transferase (10 µL, 5 U/mL, 50 mU) was added. After an additional one day at room temperature, TLC indicated the reaction was almost completed. Reverse phase column (C-18) purification gave the product (100 %).</p><heading><b><i>E. Acylation procedure</i></b></heading><p num="p0112">Steric chloride (4.3 mg, µmol) was added to a solution of the above product (16 mg, 14.3 µmol) and NaHCO<sub>3</sub> (20 mL) in THF (2.0 mL) at 0°C. The reaction was stirred for 2 h, after which the product was purified by reverse phase column chromatography(C-18 column, methanol and water, 20 : 80 to 100:0) to give the product (20 mg, 100%).</p><heading><b><u style="single">Results and Conclusions:</u></b></heading><p num="p0113">Since lactosylceramide was found to be an extremely poor substrate for either bacterial or mammalian α-2,3-sialyl transferases, it was converted to the lactosylsphingosine prior to enzymatic glycosylations (see scheme). Different basic hydrolysis condition were studied, and reactions with KOH in MeOH or anhydrous hydrazine gave comparable yields (71% and 63%, respectively). Sialyltransferase catalyzed reaction was found to be slow, after thirteen days at room temperature the reaction produced sialyl lactosylsphingosine in 43% isolated yield, with the recovery of 32% lactosylsphingosine. The reaction catalyzed by GalNAc-transferase and final chemical acylation all proceeded well, each providing the corresponding products in quantitative yields.</p><p num="p0114">It is understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and scope of the appended claims. All publications, patents, and patent applications cited herein are hereby incorporated by reference for all purposes.<!-- EPO <DP n="37"> --> Some additional embodiments of the invention are described in the following paragraphs.
<ol><li>1. A method of enzymatically synthesizing a glycosphingoid, the method comprising:
<ul list-style="bullet"><li>contacting a sphingoid with a glycosyltransferase reaction mixture which comprises:
<ol><li>a) one or more glycosyltransferases,</li><li>b) a corresponding nucleotide sugar for each glycosyltransferase, and</li><li>c) other reactants required for glycosyltransferase activity;</li></ol></li><li>for a sufficient time and under appropriate conditions to transfer the sugar or sugars from the nucleotide sugar to the sphingoid to form a glycosylated sphingoid; wherein method includes at least one efficiency enhancing step selected from the group consisting of:</li><li>including an organic solvent in the glycosyltransferase reaction mixture; and</li><li>using a glycosyltransferase cycle to generate the nucleotide sugar.</li></ul></li><li>2. The method of paragraph 1, wherein the method further comprises contacting the glycosylated sphingoid with a second glycosyltransferase rection mixture which comprises:
<ol><li>a) an additional glycosyltransferase,</li><li>b) a corresponding nucleotide sugar for the additional glycosyltransferase, and</li><li>c) other reactants required for activity of the additional glycosyltransferase;</li></ol>
for a sufficient time and under appropriate conditions to transfer the sugar from the nucleotide sugar to the glycosylated sphingoid.</li><li>3. The method of paragraph 1, wherein the method comprises both of the efficiency enhancing steps.<!-- EPO <DP n="38"> --></li><li>4. The method of paragraph 1, wherein the method further comprises removing the fatty acid from the sphingoid prior to contacting with the glycosyltransferase reaction mixture.</li><li>5. The method of paragraph 1, wherein the glycosyltransferase is a sialyltransferase and the nucleotide sugar comprises a sialic acid or an analog of sialic acid.</li><li>6. The method of paragraph 1, wherein the sphingoid comprises a compound having a formula I:
<chemistry id="chem0007" num="0007"><img id="ib0007" orientation="unknown" wi="63" img-format="tif" img-content="chem" file="imgb0007.tif" inline="no" he="31"/></chemistry>
wherein R<sup>1</sup> is selected from the group consisting of H, Glcβ1-, Galβ1-, and lactoseβ1-;

R2 is selected from the group consisting of CH<sub>2</sub> and
<chemistry id="chem0008" num="0008"><img id="ib0008" orientation="unknown" wi="15" img-format="tif" img-content="chem" file="imgb0008.tif" inline="no" he="14"/></chemistry>
R3 is selected from the group consisting of H, CH<sub>3</sub>, CH<sub>2</sub>CH<sub>3</sub>,
<chemistry id="chem0009" num="0009"><img id="ib0009" orientation="unknown" wi="40" img-format="tif" img-content="chem" file="imgb0009.tif" inline="no" he="20"/></chemistry>
R4 is selected from the group consisting of:
<ul list-style="bullet"><li>(i) C<sub>2</sub>-C<sub>36</sub> saturated, unsaturated, or polyunsaturated alkyl;</li><li>(ii) α-hydroxy-C<sub>2</sub>-C<sub>36</sub> alkyl;</li><li>(iii) ω-hydroxy-C<sub>2</sub>-C<sub>36</sub> alkyl;</li><li>(iv) α,ω-dihydroxy-C<sub>2</sub>-C<sub>36</sub> alkyl;</li><li>(v) ClCH<sub>2</sub>-, Cl<sub>2</sub>CH-, or Cl<sub>3</sub>C-; and</li><li>(vi) an alkanoyl group having the formula
<chemistry id="chem0010" num="0010"><img id="ib0010" orientation="unknown" wi="30" img-format="tif" img-content="chem" file="imgb0010.tif" inline="no" he="18"/></chemistry></li></ul><!-- EPO <DP n="39"> -->
in which R<sup>6</sup> is either a divalent C<sub>2</sub>-C<sub>36</sub> alkyl or a divalent α-hydroxy-C<sub>2</sub>-C<sub>36</sub> alkyl, and R<sup>7</sup> is either a monovalent C<sub>2</sub>-C<sub>36</sub> alkyl or a monovalent α-hydroxy-C<sub>2</sub>-C<sub>36</sub> alkyl; and

R<sup>5</sup> is selected from the group consisting of a saturated, unsaturated, or polyunsaturated C<sub>2</sub>-C<sub>37</sub> alkyl group.</li><li>7. The method of paragraph 1, wherein the sphingoid comprises a compound having a formula:
<chemistry id="chem0011" num="0011"><img id="ib0011" orientation="unknown" wi="46" img-format="tif" img-content="chem" file="imgb0011.tif" inline="no" he="28"/></chemistry>
wherein R<sup>1</sup> is selected from the group consisting of H, Glcβ1-, Galβ1-, lactoseβ1-, and an oligosaccharide;

R<sup>2</sup> is selected from the group consisting of H and a saturated or unsaturated C<sub>2</sub>-C<sub>26</sub> alkyl group, and a protecting group; and

R<sup>3</sup> is a saturated, unsaturated, or polyunsaturated C<sub>2</sub>-C<sub>37</sub> alkyl group, or a protecting group.</li><li>8. The method of paragraph 7, wherein the sphingoid is selected from the group consisting of:
<ol><li>a) ceramide (Cer);</li><li>b) Glcβ1-Cer</li><li>c) Galβ1-Cer;</li><li>d) Gal4Glcβ1-Cer;</li><li>e) Neu5Ac3Gal4GlcCer;</li><li>f) GalNAc4(Neu5Ac3)Gal4GlcCer;</li><li>g) Neu5Ac3Gal3GalNAc4Gal4GlcCer;</li><li>h) Neu5Ac8Neu5Ac3Gal4GlcCer;</li><li>i) GalNAc4(Neu5Ac8Neu5Ac3)Gal4GlcCer;</li><li>j) Neu5Ac3Gal3GalNAc4(Neu5Ac3)Gal4GlcCer;<!-- EPO <DP n="40"> --></li><li>k) Neu5Ac3Gal3(Neu5Ac6)GalNAc4Gal4GlcCer;</li><li>l) Gal3GalNAc4(Neu5Ac8Neu5Ac3)Gal4GlcCer;</li><li>m) Neu5Ac8Neu8Ac3Gal3GalNAc4(Neu5Ac3)Gal4GlcCer;</li><li>n) Neu5Ac3Gal3GalNAc4(Neu5Ac8Neu5Ac3)Gal4GlcCer;</li><li>o) Gal3GalNAc4(Neu5Ac8Neu5Ac8Neu5Ac3)Gal4GlcCer; and</li><li>p) Neu5Ac8Neu5Ac3Gal3GalNAc4(Neu5Ac8Neu5c3)Gal4GlcCer.</li></ol></li><li>9. The method of paragraph 8, wherein the sphingoid is Neu5Ac3Ga14GlcCer, the glycosyltransferase is a β1,4-GalNAc transferase, and the nucleotide sugar is UDP-GalNAc and the product is GalNAc4Neu5Ac3Ga14GlcCer.</li><li>10. The method of paragraph 9, wherein the Neu5Ac3Ga14GlcCer is produced using a method that comprises contacting Gal4GlcCer with an α2,3-sialyltransferase and CMP-Neu5Ac.</li><li>11. The method of paragraph 10, wherein the Ga14GlcCer is produced using a method that comprises contacting GlcCer with a β1,4-galactosyltransferase and UDP-Gal.</li><li>12. The method of paragraph 11, wherein the GlcCer is a plant glycosylceramide.</li><li>13. The method of paragraph 8, wherein the sphingoid is Neu5Ac8Neu5Ac3Gal4GlcCer, the glycosyltransferase is a β1,4-GalNAc transferase, the nucleotide sugar is UDP-GalNAc and the product is

GalNAc4(Neu5Ac8Neu5Ac3)Gal4GlcCer.</li><li>14. The method of paragraph 1, wherein the sphingoid is a ceramide.</li><li>15. The method of paragraph 1, wherein the sphingoid comprises one or more saccharide residues.<!-- EPO <DP n="41"> --></li><li>16. The method of paragraph 15, wherein the method further comprises removal of one or more saccharide residues prior to contacting the sphingoid with the glycosyltransferase reaction mixture.</li><li>17. A method of enzymatically synthesizing a ganglioside, the method comprising:
<ol><li>(a) contacting a compound of the formula Glcβ-OR with a β1,4-galactosyltransferase in the presence of UDP-galactose under conditions sufficient to transfer galactose from the UDP-galactose to form a compound having the formula Galβ(1-4)Glcβ-OR; and</li><li>(b) contacting the compound formed in (a) with an α2,3-sialyltransferase in the presence of CMP-sialic acid under conditions sufficient to transfer sialic acid from the CMP-sialic acid to form a compound having the formula Siaα(2-3)Galβ(1-4)Glc-β-OR;</li></ol>
wherein R is a sphingoid, and the method comprises performing at least one efficiency enhancing step selected from the group consisting of:
<ul list-style="bullet"><li>including an organic solvent in the glycosyltransferase reaction mixture; and</li><li>using a glycosyltransferase cycle to generate the either or both of the UDP-galactose and the CMP-sialic acid.</li></ul></li><li>18. The method of paragraph 17, wherein the method further comprises removing a fatty acid from the sphingoid prior to contacting with the glycosyltransferase reaction mixture.</li><li>19. The method of paragraph 17, wherein R is selected from the group consisting of sphingosines, phytosphingosines, sphinganines, and ceramides.</li><li>20. The method of paragraph 17, wherein the method further comprises contacting the compound formed in (a) or the compound formed in (b) with a β1,4-galactosaminyltransferase in the presence of UDP-GalNAc under conditions in which<!-- EPO <DP n="42"> --> GalNAc is transferred to form a compound having a formula GalNAcβ(1-4)Galβ(1-4)Glcβ-OR or GalNAcβ(1-4)(Siaα(2-3))Galβ(1-4)Glcβ-OR, respectively.</li><li>21. The method of paragraph 20, wherein the method further comprises contacting the compound having the formula GalNAcβ(1-4)Galβ(1-4)Glcβ-OR or GalNAcβ(1-4)(Siaa(2-3))Galβ(1-4)Glcβ-OR with a β1,3-galactosyltransferase in the presence of UDP-Gal, under conditions in which Gal is transferred to form a galactosyl compound having a formula Galβ(1-3)GalNAcβ(1-4)Galβ(1-4)Glcβ-OR or Galβ(1-3)GalNAcβ(1-4)(Siaα(2-3)) Galβ(1-4)Glcβ-OR.</li><li>22. The method of paragraph 21, wherein the method further comprises contacting the galactosyl compound with an α2,3-sialyltransferase in the presence of CMP sialic acid under conditions sufficient to transfer sialic acid from the CMP-sialic acid to form a sialylated compound having a formula selected from the group consisting of Siaα(2,3)Galβ(1-3)GalNAcβ(1-4)Galβ(1-4)Glcβ-OR and Siaa(2,3)Galβ(1-3)GalNAcβ(1-4)(Siaα(2-3))Galβ(1-4)Glcβ-OR.</li><li>23. The method of paragraph 22, wherein the method further comprises contacting the sialylated compound with an α2,8-sialyltransferase and CMP-sialic acid under conditions in which a sialic acid residue is transferred from the CMP-sialic acid to form a compound having a formula selected from the group consisting of:
<ul list-style="bullet"><li>Siaα(2,8)Siaα(2,3)Galβ(1-3)GalNAcβ(1-4)Galβ(1-4)Glcβ-OR;</li><li>Siaα(2,8)Siaα(2,3)Galβ(1-3)GalNAcβ(1-4)(Siaα(2-3))Galβ(1-4)Glcβ-OR;</li><li>Siaα(2,8)Siaα(2,3)Galβ(1-3)GalNAcβ(1-4)(Siaα(2-3))Gaβ(1-4)Glcβ-OR;</li><li>Siaα(2,3)Galβ(1-3)GalNAcβ(1-4)(Siaα(2,8)Siaα(2-3)) OR; and</li><li>Siaα(2,8)Siaα(2,3)Galβ(1-3)GalNAcβ(1-4)(Siaα(2,8)Siaα (2-3))Galβ(1-4)Glcβ-OR.</li></ul></li><li>24. The method of paragraph 17, wherein the method further comprises contacting the compound having the formula Siaα(2-3)Galβ(1-4)Glc-β-OR with an<!-- EPO <DP n="43"> --> α2,8-sialyltransferase and CMP-sialic acid under conditions in which a sialic acid residue is transferred from the CMP-sialic acid to form a compound having the formula Siaα(2-8)Siaα(2-3)Galβ(1-4)Glc-β-OR.</li><li>25. The method of paragraph 24, wherein the method further comprises contacting the compound having the formula Siaa(2-8)Siaα(2-3)Galβ(1-4)Glc-β-OR with a β1,4-galactosaminyltransferase in the presence of UDP-Ga1NAc under conditions in which GalNAc is transferred to form a compound having a formula GalNAcβ(1-4)(Siaα(2-8)Siaα(2-3)Galβ(1-4)Glcβ-OR.</li><li>26. The method of paragraph 25, wherein the method further comprises contacting the compound having the formula GalNAcβ(1-4)(Siaα(2-8)Siaα(2-3))Galβ(1-4)Glcβ-OR with a β1,3-galactosyltransferase in the presence of UDP-Gal, under conditions in which Gal is transferred to form a galactosyl compound having a formula Galβ(1-3)GalNAcβ(1-4)(Siaα(2-8)Siaα(2-3))Gaβ(1-4)Glcβ-OR.</li><li>27. The method of paragraph 26, wherein the method further comprises contacting the galactosyl compound with an α2,3-sialyltransferase in the presence of CMP-sialic acid under conditions sufficient to transfer sialic acid from the CMP-sialic acid to form a sialylated compound having a formula Siaα(2-3)Galβ(1-3)GalNAcβ(1-4)(Siaα(2-8)Siaα(2-3))Galβ(1-4)Glcβ-OR.</li><li>28. The method of paragraph 27, wherein the method further comprises contacting the sialylated compound with an α2,8-sialyltransferase and CMP-sialic acid under conditions in which a sialic acid residue is transferred from the CMP-sialic acid to form a compound having a formula Siaα(2-8)Siaα(2-3)Galβ(1-3)GalNAcβ(1-4)(Siaα(2-8)Siaα(2-3))Galβ(1-4)Glcβ-OR.</li><li>29. The method of paragraph 17, wherein the method further comprises contacting the compound formed in step (a) or the compound formed in step (b) with a β1,3-glucosaminyltransferase in the presence of UDP-GlcNAc under conditions in<!-- EPO <DP n="44"> --> which GlcNAc is transferred to form a compound having a formula GlcNAcβ(1-4)Galβ(1-4)Glcβ-OR or GlcNAcβ(1-4)(Siaα(2-3))Galβ(1-4)Glcβ-OR, respectively.</li><li>30. The method of paragraph 29, wherein the method further comprises contacting the compound having the formula GlcNAcβ(1-4)Galβ(1-4)Glcβ-OR or GlcNAcβ(1-4)(Siaα(2-3))Galβ(1-4)Glcβ-OR with a β1,3-galactosyltransferase or a β1,4-galactosyltransferase in the presence of UDP-Gal, under conditions in which Gal is transferred to form a galactosylated compound having a formula selected from the group consisting of:
<ul list-style="bullet"><li>Galβ(1-3)GlcNAcβ(1-4)Galβ(1-4)Glcβ-OR;</li><li>Galβ(1-4)GlcNAcβ(1-4)Galβ(1-4)Glcβ-OR;</li><li>Galβ(1-3)GlcNAcβ(1-4)(Siaα(2-3))Galβ(1-4)Glcβ-OR; and</li><li>Galβ(1-4)GlcNAcβ(1-4)(Siaα(2-3))Galβ(1-4)Glcβ-OR.</li></ul></li><li>31. The method of paragraph 30, wherein the method further comprises contacting the galactosyl compound with an α2,3-sialyltransferase in the presence of CMP-sialic acid under conditions sufficient to transfer sialic acid from the CMP-sialic acid to form a sialylated compound having a formula selected from the group consisting of:
<ul list-style="bullet"><li>Siaα(2-3)Galβ(1-3)GlcNAcβ(1-4)Galβ(1-4)Glcβ-OR;</li><li>Siaa(2-3)Galβ(1-4)GlcNAcβ(1-4)Galβ(1-4)Glcβ-OR;</li><li>Siaα(2-3)Galβ(1-3)GlcNAcβ(1-4)(Siaα,(2-3))Galβ(1-4)Glcβ-OR and</li><li>Siaα(2-3)Galβ(1-4)GlcNAcβ(1-4)(Siaα(2-3))Galβ(1-4)Glcβ-OR.</li></ul></li><li>32. The method of paragraph 31, wherein the method further comprises contacting the sialylated compound with an α2,8-sialyltransferase and CMP-sialic acid under conditions in which a sialic acid residue is transferred from the CMP-sialic acid to form a compound having a formula selected from the group consisting of:
<ul list-style="bullet"><li>Siaα(2-8)Siaα(2-3)Galβ(1-3)GlcNAcβ(1-4)Galβ(1-4)Glcβ-OR;</li><li>Siaα(2-8)Siaα(2-3)Galβ(1-4)GlcNAcβ(1-4)Galβ(1-4)Glcβ-OR;</li><li>Siaα(2-3)Galβ(1-3)GlcNAcβ(1-4)(Siaα(2-8)Siaα(2-3))Galβ(1-4)Glcβ-OR;<!-- EPO <DP n="45"> --></li><li>Siaα(2-3)Galβ(1-4)GlcNAcβ(1-4)(Siaα(2-8)Siaα(2-3))Galβ(1-4)Glcβ-OR;</li><li>Siaα(2-8)Siaα(2-3)Galβ(1-3)GlcNAcβ(1-4)(Siaα(2-3))Galβ(1-4)Glcβ-OR; and</li><li>Siaα(2-8)Siaα(2-3 )Galβ(1-4)GlcNAcβ(1-4)(Siaα(2-3))Galβ(1-4)Glcβ-OR.</li></ul></li><li>33. A method of enzymatically galactosylating a glycosphingoid, the method comprising contacting the glycosphingoid with a β-galactosidase and a compound having the formula Gal-X, where X is a leaving group, under conditions suitable for transfer of the Gal residue from the Gal-X to the glycosphingoid to form a galactosylated glycosphingoid.</li><li>34. The method of paragraph 33, wherein the glycosphingoid is glucosylceramide, the galactsidase is a β1,4-galactosidase, and the galactosylated glycosphingoid is lactosylceramide.</li><li>35. The method of paragraph 33, wherein the method further comprises contacting the galactosylated glycosphingoid with a sialyltransferase in the presence of CMP-sialic acid under conditions sufficient to transfer sialic acid from the CMP-sialic acid to form a sialylated galactosylglycosphingoid.</li><li>36. The method of paragraph 35, wherein the galactosylated glycosphingoid is lactosylceramide, the sialyltransferase is an α2,3-sialyltransferase, and the sialylated galactosylglycosphingoid is ganglioside GM3.</li></ol></p></description><claims load-source="ep" status="new" lang="EN"><claim id="c-en-0001" num="0001"><claim-text>A method of enzymatically synthesizing a glycosylated sphingoid, the method comprising:
<claim-text>contacting a sphingoid with a glycosyltransferase reaction mixture that comprises:
<claim-text>a) one or more glycosyltransferases,</claim-text><claim-text>b) a corresponding nucleotide sugar for each glycosyltransferase, and</claim-text><claim-text>c) other reactants required for glycosyltransferase activity;</claim-text></claim-text><claim-text>for a sufficient time and under appropriate conditions to transfer the sugar or sugars from the nucleotide sugars to the sphingoid to form the glycosylated sphingoid; wherein method includes at least one efficiency enhancing step selected from the group consisting of:</claim-text><claim-text>using a glycosyltransferase cycle to generate the nucleotide sugar;</claim-text><claim-text>removing the fatty acid from the sphingoid prior to contacting with the glycosyltransferase reaction mixture; and</claim-text><claim-text>including an organic solvent in the glycosyltransferase reaction mixture.</claim-text></claim-text></claim><claim id="c-en-0002" num="0002"><claim-text>The method of claim 1, wherein the method further comprises contacting the glycosylated sphingoid with at least a second glycosyltransferase reaction mixture which comprises:
<claim-text>a) one or more additional glycosyltransferases,</claim-text><claim-text>b) a corresponding nucleotide sugar for the additional glycosyltransferases, and</claim-text><claim-text>c) other reactants required for activity of the additional glycosyltransferases;</claim-text>
for a sufficient time and under appropriate conditions to transfer the sugar from the nucleotide sugar to the glycosylated sphingoid.<!-- EPO <DP n="47"> --></claim-text></claim><claim id="c-en-0003" num="0003"><claim-text>The method of claim 1 or claim 2, wherein the method comprises at least two of the efficiency enhancing steps.</claim-text></claim><claim id="c-en-0004" num="0004"><claim-text>The method according to any one of the preceding claims, wherein the glycosyltransferase is a β1,4galactosaminyltransferase and the nucleotide sugar is UDP-GalNAc.</claim-text></claim><claim id="c-en-0005" num="0005"><claim-text>The method of claim 1, wherein the glycosyltransferase is a sialyltransferase and the nucleotide sugar comprises a sialic acid or an analog of sialic acid.</claim-text></claim><claim id="c-en-0006" num="0006"><claim-text>The method according to any one of the preceding claims, wherein the sphingoid comprises a compound having a formula I:
<chemistry id="chem0012" num="0012"><img id="ib0012" orientation="unknown" wi="63" img-format="tif" img-content="chem" file="imgb0012.tif" inline="no" he="35"/></chemistry>
wherein R<sup>1</sup> is selected from the group consisting of H, Glcβ1-, Galβ1-, and lactoseoβ1-;

R2 is selected from the group consisting of CH<sub>2</sub> and
<chemistry id="chem0013" num="0013"><img id="ib0013" orientation="unknown" wi="19" img-format="tif" img-content="chem" file="imgb0013.tif" inline="no" he="15"/></chemistry>
R3 is selected from the group consisting of H, CH<sub>3</sub>, CH<sub>2</sub>CH<sub>3</sub><chemistry id="chem0014" num="0014"><img id="ib0014" orientation="unknown" wi="44" img-format="tif" img-content="chem" file="imgb0014.tif" inline="no" he="24"/></chemistry>
R4 is selected from the group consisting of:
<claim-text>(I) C<sub>2</sub>-C<sub>36</sub> saturated, unsaturated, or<!-- EPO <DP n="48"> --> polyunsaturated alkyl;</claim-text><claim-text>(ii) α-hydroxy-C<sub>2</sub>-C<sub>36</sub> alkyl;</claim-text><claim-text>(iii) ω-hydroxy-C<sub>2</sub>-C<sub>36</sub> alkyl;</claim-text><claim-text>(iv) α,ω-dihydroxy-C<sub>2</sub>-C<sub>36</sub> alkyl;</claim-text><claim-text>(v) ClCH<sub>2</sub>-, Cl<sub>2</sub>CH-, or Cl<sub>3</sub>C-; and</claim-text><claim-text>(vi) an alkanoyl group having the formula
<chemistry id="chem0015" num="0015"><img id="ib0015" orientation="unknown" wi="28" img-format="tif" img-content="chem" file="imgb0015.tif" inline="no" he="14"/></chemistry></claim-text>
in which R<sup>6</sup> is either a divalent C<sub>2</sub>-C<sub>36</sub> alkyl or a divalent α-hydroxy- C<sub>2</sub>-C<sub>36</sub> alkyl, and R<sup>7</sup> is either a monovalent C<sub>2</sub>-C<sub>36</sub> alkyl or a monovalent α-hydroxy- C<sub>2</sub>-C<sub>36</sub> alkyl; and

R<sup>5</sup> is selected from the group consisting of a saturated, unsaturated, or polyunsaturated C<sub>2</sub>-C<sub>37</sub> alkyl group.</claim-text></claim><claim id="c-en-0007" num="0007"><claim-text>The method according to any one of claims 1 to 5, wherein the sphingoid comprises a compound having a formula:
<chemistry id="chem0016" num="0016"><img id="ib0016" orientation="unknown" wi="47" img-format="tif" img-content="chem" file="imgb0016.tif" inline="no" he="29"/></chemistry>
wherein R<sup>1</sup> is selected from the group consisting of H, Glcβ1-, Galβ1-, lactoseβ1-, and an oligosaccharide;

R<sup>2</sup> is selected from the group consisting of H and a saturated or unsaturated C<sub>2</sub>-C<sub>26</sub> alkyl group, and a protecting group; and

R<sup>3</sup> is a saturated, unsaturated, or polyunsaturated C<sub>2</sub>-C<sub>37</sub> alkyl group, or a protecting group.</claim-text></claim><claim id="c-en-0008" num="0008"><claim-text>The method of claim 7, wherein the sphingoid is selected from the group consisting of:
<claim-text>a) ceramide (Cer);</claim-text><claim-text>b) Glcβ1-Cer<!-- EPO <DP n="49"> --></claim-text><claim-text>c) Galβ1-Cer;</claim-text><claim-text>d) Gal4Glcβ1-Cer;</claim-text><claim-text>e) Neu5Ac3Gal4GlcCer;</claim-text><claim-text>f) GalNAc4(Neu5Ac3)Gal4GlcCer;</claim-text><claim-text>g) Neu5Ac3Gal3GalNAc4Gal4GlcCer;</claim-text><claim-text>h) Neu5Ac8Neu5Ac3Gal4GlcCer;</claim-text><claim-text>I) GalNAc4(Neu5Ac8Neu5Ac3)Gal4GlcCer;</claim-text><claim-text>j) Neu5Ac3Gal3GalNAc4(Neu5Ac3)Gal4GlcCer;</claim-text><claim-text>k) Neu5Ac3Gal3(Neu5Ac6)GalNAc4Gal4GlcCer;</claim-text><claim-text>l) Gal3GalNAc4(Neu5Ac8Neu5Ac3)Gal4GlcCer;</claim-text><claim-text>m) Neu5Ac8Neu5Ac3Gal3GalNAc4(Neu5Ac3)Gal4GlcCer;</claim-text><claim-text>n) Neu5Ac3Gal3GalNAc4(Neu5Ac8Neu5Ac3)Gal4GlcCer;</claim-text><claim-text>o) Gal3GalNAc4(Neu5Ac8Neu5Ac8Neu5Ac3)Gal4GlcCer; and</claim-text><claim-text>p) Neu5Ac8Neu5Ac3Gal3GalNAc4(Neu5Ac8Neu5c3)Gal4GlcCer.</claim-text></claim-text></claim><claim id="c-en-0009" num="0009"><claim-text>The method of claim 8, wherein the sphingoid is Neu5Ac3Gal4GlcCer, the glycosyltransferase is a β1,4-GalNAc transferase, and the nucleotide sugar is UDP-GalNAc and the product is GalNAc4Neu5Ac3Gal4GlcCer.</claim-text></claim><claim id="c-en-0010" num="0010"><claim-text>The method of claim 9, wherein the Neu5Ac3Gal4GlcCer is produced using a method that comprises contacting Gal4GlcCer with an α2,3-sialyltransferase and CMP-Neu5Ac.</claim-text></claim><claim id="c-en-0011" num="0011"><claim-text>The method of claim 10, wherein the Gal4GlcCer is produced using a method that comprises contacting GlcCer with a β1,4-galactosyltransferase and UDP-Gal.</claim-text></claim><claim id="c-en-0012" num="0012"><claim-text>The method of claim 11, wherein the GlcCer is a plant glycosylceramide.</claim-text></claim><claim id="c-en-0013" num="0013"><claim-text>The method of claim 8, wherein the sphingoid is<!-- EPO <DP n="50"> --> Neu5Ac8Neu5Ac3Gal4GlcCer, the glycosyltransferase is a β1,4-GalNAc transferase, the nucleotide sugar is UDP-GalNAc and the product is

GalNAc4(Neu5Ac8Neu5Ac3)Gal4GlcCer.</claim-text></claim><claim id="c-en-0014" num="0014"><claim-text>The method according to any one of claims 1 to 5, wherein the sphingoid is a ceramide.</claim-text></claim><claim id="c-en-0015" num="0015"><claim-text>The method according to any one of claims 1 to 5, wherein the sphingoid comprises one or more saccharide residues.</claim-text></claim><claim id="c-en-0016" num="0016"><claim-text>The method of claim 15, wherein the method further comprises removal of one or more saccharide residues prior to contacting the sphingoid with the glycosyltransferase reaction mixture.</claim-text></claim><claim id="c-en-0017" num="0017"><claim-text>A method of enzymatically synthesizing a ganglioside, the method comprising:
<claim-text>(a) contacting a compound of the formula Glcβ-OR with a β1,4-galactosyltransferase in the presence of UDP-galactose under conditions sufficient to transfer galactose from the UDP-galactose to form a compound having the formula Galβ(1-4)Glcβ-OR; and</claim-text><claim-text>(b) contacting the compound formed in (a) with an α2,3-sialyltransferase in the presence of CMP-sialic acid under conditions sufficient to transfer sialic acid from the CMP-sialic acid to form a compound having the formula Siaa(2-3)Galβ(1-4)Glc-β-OR;

wherein R is a sphingoid, and the method comprises performing at least one efficiency enhancing step selected from the group consisting of:
<claim-text>using a glycosyltransferase cycle to generate the either or both of the UDP-galactose and the CMP-sialic acid;</claim-text><claim-text>removing the fatty acid from the sphingoid prior to contacting with the<!-- EPO <DP n="51"> --> glycosyltransferase reaction mixture; and</claim-text><claim-text>including an organic solvent in the glycosyltransferase reaction mixture.</claim-text></claim-text></claim-text></claim><claim id="c-en-0018" num="0018"><claim-text>The method of claim 17, wherein R is selected from the group consisting of sphingosines, phytosphingosines, sphinganines, and ceramides.</claim-text></claim><claim id="c-en-0019" num="0019"><claim-text>The method of claim 17, wherein the method further comprises contacting the compound formed in (a) or the compound formed in (b) with a β1,4-galactosaminyltransferase in the presence of UDP-GalNAc under conditions in which GalNAc is transferred to form a compound having a formula GalNAcβ(1-4)Galβ(1-4)Glcβ-OR or GalNAcβ(1-4)(Siaα(2-3))Galβ(1-4)Glcβ-OR, respectively.</claim-text></claim><claim id="c-en-0020" num="0020"><claim-text>The method of claim 19, wherein the method further comprises contacting the compound having the formula GalNAcβ(1-4)Galβ(1-4)Glcβ-OR or GalNAcβ(1-4)(Siaα(2-3))Galβ(1-4)Glcβ-OR with a β1,3-galactosyltransferase in the presence of UDP-Gal, under conditions in which Gal is transferred to form a galactosyl compound having a formula Galβ(1-3)GalNAcβ(1-4)Galβ(1-4)Glcβ-OR or Galβ(1-3)GalNAcβ(1-4)(Siaα(2-3)) Gal β(1-4)Glcβ-OR.</claim-text></claim><claim id="c-en-0021" num="0021"><claim-text>The method of claim 20, wherein the method further comprises contacting the galactosyl compound with an α2,3-sialyltransferase in the presence of CMP sialic acid under conditions sufficient to transfer sialic acid from the CMP-sialic acid to form a sialylated compound having a formula selected from the group consisting of Siaα(2,3)Galβ(1-3)GalNAcβ(1-4)Galβ(1-4)Glcβ-OR and Siaα(2,3)Galβ(1-3)GalNAcβ(1-4)(Siaα(2-3))Galβ(1-4)Glcβ-OR.</claim-text></claim><claim id="c-en-0022" num="0022"><claim-text>The method of claim 21, wherein the method further comprises contacting the sialylated compound with an α2,8-sialyltransferase and CMP-sialic acid under conditions in which a sialic acid residue is transferred from the CMP-sialic acid to form a<!-- EPO <DP n="52"> --> compound having a formula selected from the group consisting of:
<claim-text>Siaα(2,8)Siaα(2,3)Galβ(1-3)GalNAcβ(1-4)Galβ(1-4)Glcβ-OR;</claim-text><claim-text>Siaα(2,8)Siaα(2,3)Galβ(1-3)GalNAcβ(1-4)(Siaα(2-3))Galβ(1-4)Glcβ-OR;</claim-text><claim-text>Siaα(2,8)Siaα(2,3)Galβ(1-3)GalNAcβ(1-4)(Siaα(2-3))Galβ(1-4)Glcβ-OR;</claim-text><claim-text>Siaα(2,3)Galβ(1-3)GalNAcβ(1-4)(Siaα(2,8)Siaα(2-3)) OR; and</claim-text><claim-text>Siaα(2,8)Siaα(2,3)Galβ(1-3)GalNAcβ(1-4)(Siaα(2,8)Siaα (2-3))Galβ(1-4)Glcβ-OR.</claim-text></claim-text></claim><claim id="c-en-0023" num="0023"><claim-text>The method of claim 17, wherein the method further comprises contacting the compound having the formula Siaα(2-3)Galβ(1-4)Glc-β-OR with an α2,8-sialyltransferase and CMP-sialic acid under conditions in which a sialic acid residue is transferred from the CMP-sialic acid to form a compound having the formula Siaα(2-8)Siaα(2-3)Galβ(1-4)Glc-β-OR.</claim-text></claim><claim id="c-en-0024" num="0024"><claim-text>The method of claim 23, wherein the method further comprises contacting the compound having the formula Siaα(2-8)Siaα(2-3)Galβ(1-4)Glc-β-OR with a β1,4-galactosaminyltransferase in the presence of UDP-GalNAc under conditions in which GalNAc is transferred to form a compound having a formula GalNAcβ(1-4)(Siaα(2-8)Siaα(2-3))Galβ(1-4)Glcβ-OR.</claim-text></claim><claim id="c-en-0025" num="0025"><claim-text>The method of claim 24, wherein the method further comprises contacting the compound having the formula GalNAcβ(1-4)(Siaα(2-8)Siaα(2-3))Galβ(1-4)Glcβ-OR with a β1,3-galactosyltransferase in the presence of UDP-Gal, under conditions in which Gal is transferred to form a galactosyl

compound having a formula Galβ(1-3)GalNAcβ(1-4)(Siaα(2-8)Siaα(2-3))Galβ(1-4)Glcβ-OR.</claim-text></claim><claim id="c-en-0026" num="0026"><claim-text>The method of claim 25, wherein the method further comprises contacting<!-- EPO <DP n="53"> --> the galactosyl compound with an α2,3-sialyltransferase in the presence of CMP-sialic acid under conditions sufficient to transfer sialic acid from the CMP-sialic acid to form a sialylated compound having a formula Siaα(2-3)Galβ(1-3)GalNAcβ(1-4)(Siaα(2-8)Siaα(2-3))Galβ(1-4)Glcβ-OR.</claim-text></claim><claim id="c-en-0027" num="0027"><claim-text>The method of claim 26, wherein the method further comprises contacting the sialylated compound with an α2,8-sialyltransferase and CMP-sialic acid under conditions in which a sialic acid residue is transferred from the CMP-sialic acid to form a compound having a formula Siaα(2-8)Siaα(2-3)Galβ(1-3)GalNAcβ(1-4)(Siaα(2-8)Siaα(2-3))Galβ(1-4)Glcβ-OR.</claim-text></claim><claim id="c-en-0028" num="0028"><claim-text>The method of claim 17, wherein the method further comprises contacting the compound formed in step (a) or the compound formed in step (b) with a β1,3-glucosaminyltransferase in the presence of UDP-GlcNAc under conditions in which GlcNAc is transferred to form a compound having a formula GlcNAcβ(1-4)Galβ(1-4)Glcβ-OR or GlcNAcβ

(1-4)(Siaα(2-3))Galβ(1-4)Glcβ-OR, respectively.</claim-text></claim><claim id="c-en-0029" num="0029"><claim-text>The method of claim 28, wherein the method further comprises contacting the compound having the formula GlcNAcβ(1-4)Galβ(1-4)Glcβ-OR or GlcNAcβ(1-4)(Sia(2-3))Galβ(1-4)Glcβ-OR with a β1,3-galactosyltransferase or a β1,4-galactosyltransferase in the presence of UDP-Gal, under conditions in which Gal is transferred to form a galactosylated compound having a formula selected from the group consisting of:
<claim-text>Galβ(1-3)GlcNAcβ(1-4)Galβ(1-4)Glcβ-OR;</claim-text><claim-text>Galβ(1-4)GlcNAcβ(1-4)Galβ(1-4)Glcβ-OR;</claim-text><claim-text>Galβ(1-3)GlcNAcβ(1-4)(Siaα(2-3))Galβ(1-4)Glcβ-OR; and</claim-text><claim-text>Galβ(1-4)GlcNAcβ(1-4)(Siaα(2-3))Galβ(1-4)Glcβ-OR.</claim-text><!-- EPO <DP n="54"> --></claim-text></claim><claim id="c-en-0030" num="0030"><claim-text>The method of claim 29, wherein the method further comprises contacting the galactosyl compound with an α2,3-sialyltransferase in the presence of CMP-sialic acid under conditions sufficient to transfer sialic acid from the CMP-sialic acid to form a sialylated compound having a formula selected from the group consisting of:
<claim-text>Siaα(2-3)Galβ(1-3)GlcNAcβ(1-4)Galβ(1-4)Glcβ-OR; Siaa(2-3 )GalP(1-4)GlcNAcβ(1-4)Galβ(1-4)Glcβ-OR; Siaα(2-3)Galβ(1-3)GlcNAcβ(1-4)(Siaα(2-3))Galβ(1-4)Glcβ-OR and</claim-text><claim-text>Siaα(2-3)Galβ(1-4)GlcNAcβ(1-4)(Siaα(2-3))Galβ(1-4)Glcβ-OR.</claim-text></claim-text></claim><claim id="c-en-0031" num="0031"><claim-text>The method of claim 30, wherein the method further comprises contacting the sialylated compound with an α2,8-sialyltransferase and CMP-sialic acid under conditions in which a sialic acid residue is transferred from the CMP-sialic acid to form a compound having a formula selected from the group consisting of:
<claim-text>Siaα(2-8)Siaα(2-3)Galβ(1-3)GlcNAcβ(1-4)Galβ(1-4)Glcβ-OR;</claim-text><claim-text>Siaα(2-8)Siaα(2-3)Galβ(1-4)GlcNAcβ(1-4)Galβ(1-4)Glcβ-OR;</claim-text><claim-text>Siaα(2-3)Galβ(1-3)GlcNAcβ(1-4)(Siaα(2-8)Siaα(2-3))Galβ(1-4)Glcβ-OR;</claim-text><claim-text>Siaα(2-3)Galβ(1-4)GlcNAcβ(1-4)(Siaα(2-8)Siaα(2-3))Galβ(1 -4)Glcp-OR;</claim-text><claim-text>Siaα(2-8)Siaα(2-3)Galβ(1-3)GlcNAcβ(1-4)(Siaα(2-3))Galβ(1-4)Glcβ-OR; and</claim-text><claim-text>Siaα(2-8)Siaα(2-3)Galβ(1-4)GlcNAcβ(1-4)(Siaα(2-3))Galβ(1-4)Glcβ-OR.</claim-text></claim-text></claim><claim id="c-en-0032" num="0032"><claim-text>A method of enzymatically galactosylating a glycosphingoid, the method comprising contacting the glycosphingoid with a β-galactosidase and a compound having the formula Gal-X, where X is a leaving group, under conditions suitable for transfer of the Gal residue from the Gal-X to the glycosphingoid to form a galactosylated glycosphingoid.</claim-text></claim><claim id="c-en-0033" num="0033"><claim-text>The method of claim 32, wherein the glycosphingoid is glucosylceramide, the galactsidase is a β1,4-galactosidase, and the galactosylated glycosphingoid is<!-- EPO <DP n="55"> --> lactosylceramide.</claim-text></claim><claim id="c-en-0034" num="0034"><claim-text>The method of claim 32, wherein the method further comprises contacting the galactosylated glycosphingoid with a sialyltransferase in the presence of CMP-sialic acid under conditions sufficient to transfer sialic acid from the CMP-sialic acid to form a sialylated galactosylglycosphingoid.</claim-text></claim><claim id="c-en-0035" num="0035"><claim-text>The method of claim 34, wherein the galactosylated glycosphingoid is lactosylceramide, the sialyltransferase is an α2,3-sialyltransferase, and the sialylated galactosylglycosphingoid is ganglioside GM3.</claim-text></claim></claims><copyright>User acknowledges that Matrixware and its third party providers retain all right, title and interest in and to this xml under applicable copyright laws.  User acquires no ownership rights to this xml including but not limited to its format.  User hereby accepts the terms and conditions of the Licence Agreement set forth at http://www.matrixware.com/legal/marec/data_licence.html</copyright></patent-document>